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1 Abbreviations
aa-dUTP 5-(3-Aminoallyl)-2’-deoxyuridine 5’-triphosphate
ACW-proteins Anchorless cell wall proteins
ANOVA Analysis of variance
APS Ammoniumpersulfate
ATCC American type culture collection
BSA Bovine serum albumin
cDNA Complementary DNA
CFU Colony forming unit
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
clfA Clumping factor A
cna Collagen adhesion protein
CP Capsular polysaccharides
dEcIVIG IVIG depleted of E. coli specific IgGs
DEPC Diethylpyrocarbonate
DNA Deoxyribonucleic acid
dSaIVIG IVIG depleted of S. aureus specific IgGs
DTT Dithiothreitol
ECL Enhanced chemiluminescence
EDTA Ethylendiaminotetraacetic acid
ELISA Enzyme linked immunosorbent assay
eno enolase
FACS Fluorescence activated cell sorting
Fig. Figure
fnbPA Fibronectin binding protein A
fnbPB Fibronectin binding protein B
fur Ferric uptake regulator
GFP Green fluorescent protein
HBSS Hank’s balanced salt solution
HI-serum Heat inactivated serum
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hp2160 hypothetical protein similar to esterase (spot ID 2160)
IEF Isoelectric focussing
IgG Immunoglobulin G
IgM Immunoglobulin M
IPG Immobilised pH gradient
Isd Iron surface determinant
IVIG Intravenous immunoglobulin preparation
IVIG-DS IVIG dialysed against PBS
kDa Kilo-Dalton
LB Luria Bertani medium
LD50 Dose that kills 50 % of tested animals
LPS Lipopolysaccharide
MALDI-TOF Matrix assisted laser desorption/ionisation time of flight
MOI Multiplicity of infection
MSCRAMM Microbial surface component recognising adhesive matrix molecules
MWCO Molecular weight cutoff
NHS-activated N-hydroxysuccinimide
OD Optical density
ON Over night
ORF Open reading frame
oxo 3-oxoacyl- (acyl-carrier protein) reductase
PBS Phosphate buffered saline
pI Isoelectric point
PMN Polymorphonuclear neutrophils
PSI Pounds per square inch
qPCR Quantitative real time PCR
RNA Ribonucleic acid
RT Room temperature
SD Standard deviation
SDS Sodium dodecyl sulfate
SERPA Serological proteome analysis
SUPRA Subtractive proteome analysis
Tris Tris(hydroxymethyl)aminomethan
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2 Introduction
2.1 Clinical relevance and pathogenicity of Staphylococcus aureus
Staphlococcus aureus is a facultatively anaerobic gram-positive coccus, belonging to the
group of Staphylococcaceae. The coagulase positive S. aureus can be found as commen-
sal on human skin, with the moist squamous epithelium of the anterior nares as its primary
habitat (Roche et al., 2003). Although not showing signs of infection about 20 % of the
human population is continuously colonised with S. aureus and another 60 % is transiently
colonised. Thus, increasing the risk for invasive infections of endogenous origin (von Eiff
et al., 2001).
As nosocomially or community acquired opportunistic pathogen, S. aureus causes minor
infections of the skin, but also serious life-threatening infections like pneumonia, endocardi-
tis, sepsis and toxic shock syndrome (Lowy, 1998) in healthy and immunocompromised
patients, representing the main causative agent of nosocomial infections (Laupland et al.,
2003).
The genome of S. aureus encodes a broad range of virulence factors, to effectively estab-
lish an infection. To date more than 40 different virulence factors playing an important role
in the pathogenicity of staphylococcal infections are known (Arvidson and Tegmark, 2001).
Functions of these virulence factors include adherence to host cell structures, evasion from
the host immune system and active damage on host cells.
Microbial adhesion to host tissue is essential during the initial steps in the pathogenesis
of most infections. Adhesion is mediated by protein adhesins of the MSCRAMM (microbial
surface component recognising adhesive matrix molecules) family, which in most cases are
covalently linked to the cell wall peptidoglycan (Foster and Hook, 1998). Common to these
MSCRAMMs is an N-terminal signal peptide, enabling translocation of the protein across
the membrane, and a C-terminal hydrophobic region, harbouring the conserved LPXTG
motive essential for covalent linkage to the bacterial cell wall (Kronvall and Jonsson, 1999;
Patti et al., 1994; Schneewind et al., 1995). Most prominent members of this family are the
fibronectin binding proteins (FnbpA and B) or clumping factor A (ClfA), a fibrinogen binding
protein (Foster and Hook, 1998). So far in total 21 proteins containing the LPXTG motive
have been identified in S. aureus by genome screenings (Roche et al., 2003).
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Besides covalently linked protein adhesins, also anchorless cell wall proteins (ACW pro-
teins) mediating adhesion to extracellular matrix components have been identified. These
proteins lack a signal peptide as well as a common sorting signal like LPXTG and are
secreted by a so far unknown mechanism. Upon secretion they are suggested to be re-
associated to the bacterial cell surface (Chhatwal, 2002). One member of this new group
of adhesins is staphylococcal enolase, which apart from its function as glycolytic enzyme
mediates binding to laminin and thereby might contribute to tissue invasion and blood dis-
semination (Carneiro et al., 2004).
Apart from adhesion, strategies for evasion from the host immune system are crucial
to further promote effective colonisation. Protein A, a covalently linked surface protein
harbouring the LPXTG motive, mediates immune evasion by binding to the FC portion
of immunoglobulin G, thereby hampering efficient opsonisation and subsequent elimina-
tion by professional phagocytes (Foster, 2005). Additional components interfering with the
immune system are staphylokinase, the capsular polysaccharides and so called super-
antigens. By binding to the T-cell receptor and the MHC class II molecule on antigen-
presenting cells, superantigens trigger a T-cell activation that results in the release of pro-
inflammatory cytokines (Llewelyn and Cohen, 2002). The excessive uncoordinated release
of pro-inflammatory cytokines, in particular TNFα, is thought to be responsible for many of
the clinical features of toxic shock syndrome (Miethke et al., 1992). In addition, S. aureus
avoids the detrimental effects of oxygen free radicals that are formed during the respiratory
burst in professional phagocytes by several mechanisms, including the yellow carotenoid
pigment as scavenger or expression of two superoxide dismutases, which remove superox-
ide radicals (Foster, 2005).
Secreted proteins like the pore-forming α-toxin, hemolysins and other cytolytic toxins (e.g.
leukocydins, Panton-Valentine-leukocydin) lead to the destruction of host cells (Tomita and
Kamio, 1997). Besides this, other toxins cause food poisoning (enterotoxins A-O), the toxic
shock syndrome (TSST-1) or the staphylococcal scalded skin syndrome, which is triggered
by the exfoliative toxins A and B (Ladhani et al., 1999).
Another important feature for the pathogenesis of staphylococcal infections is for exam-
ple the availability of iron in the iron-limited host environment. To this end S. aureus evolved
strategies to sequester iron by synthesis of high affinity iron chelators, siderophores, and
corresponding membrane associated ABC-transporter systems or covalently linked surface
proteins (iron-regulated surface determinant; Isd A, B, C, and H) for the sequestration of
heme complexed iron (Maresso and Schneewind, 2006). The importance of iron home-
ostasis was confirmed by the reduced virulence of a S. aureus mutant lacking the ferric
uptake regulator (fur) in a murine skin abscess model of infection (Horsburgh et al., 2001a).
In fact, S. aureus infections always depend on multiple virulence factors and the high re-
dundancy in the function of virulence factors is supported by several in vivo studies using
mutants lacking for example MSCRAMMs, but not preventing colonisation (Darouiche et al.,
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1997; Patel et al., 1987; Peacock et al., 1999).
2.2 Antibiotic resistance of S. aureus
To date antibiotics are the only effective therapy against S. aureus infections. However, the
steadily increasing incidence of S. aureus strains, resistant to multiple antibiotics aggra-
vates the treatment, thereby leading to increased mortality by S. aureus infections.
Today MRSA is the common denotation for those multiple resistant S. aureus, although
it was initially used for ’Methicillin resistant S. aureus’ conferred by an additional penicillin
binding protein (PBP2a). The mecA gene encoding PBP2a is located on a DNA element
termed SCCmec (staphylococcal cassette chromosome mec), site-specifically integrated
into the staphylococccal genome (Beck et al., 1986; Berger-Bachi et al., 1986).
For the treatment of infections caused by MRSA the glycopeptide antibiotic Vancomycin
still represents the antibiotic of choice. However, due to the selective pressure during treat-
ment, Vancomycin intermediate resistant S. aureus (VISA) evolved, first described in 1997
by Hiramatsu et al. (1997). In contrast to other antibiotic resistances this intermediate resis-
tance against Vancomycin is not genetically encoded. In 2002 the first case of a genetically
determined Vancomycin resistance (VRSA) was reported (Weigel et al., 2003). In this case
the vanA gene, conferring resistance to Vancomycin, was horizontally transferred from a
Vancomycin resistant Enterococcus faecalis during co-infection.
Until the late 1990s the predominant pattern of MRSA infections in the USA remained
a nosocomially acquired disease, but then MRSA from community-acquired sources (CA-
MRSA) without a history of intravenous drug use began to be described more frequently
(Corriere and Decker, 2008). In 2006 the overall prevalence of CA-MRSA in the population
was 59 %. Due to an almost three times longer stay for inpatients suffering from S. aureus
infection causing nearly thrice the cost compared to non-infected inpatients, infections with
MRSA also became an economic problem. Moreover, the treatment of infections caused by
MRSA, which accounts for almost 50 % of S. aureus related infections in several US hos-
pitals, even doubles the cost caused by infections with a methicillin susceptible S. aureus
(MSSA). The mortality rate associated with MRSA infections is with 20.7 % almost thrice
as high than observed for infections caused by susceptible S. aureus (6.7 %) (Corriere and
Decker, 2008). Next to this also the prevalence of CA-MRSA is steadily increasing. In
the United States a single clone of CA-MRSA (USA-300) has become the most prevalent
cause of staphylococcal soft tissue infections acquired in the community (King et al., 2006;
Tenover et al., 2006) and has entered the inpatient setting, causing also invasive diseases
(Davis et al., 2006; Gonzalez et al., 2006; Klevens et al., 2007).
The drastic increase in both nosocomially and community acquired MRSA related in-
fections and thereby increased mortality rates highlight the pressing need for alternative
strategies to prevent and treat S. aureus infections.
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2.3 Vaccination strategies against S. aureus
2.3.1 Active immunisation
Since first vaccination studies employing active immunisation using whole bacteria (Green-
berg et al., 1987) or staphylococcal phage lysates (Giese et al., 1996) failed to achieve
protective effects, single structures of S. aureus like the capsular polysaccharides (CP) or
adhesion molecules of the MSCRAMM family got into focus of vaccine research. These
attempts achieved at least a partial protection against S. aureus infections.
By prevention of phagocytic activity the CPs represent an important factor in the patho-
genicity of S. aureus (Kampen et al., 2005). With over 80 % serotypes 5 and 8 are the
most prevalent of the 11 different serotypes among S. aureus isolates (Sompolinsky et al.,
1985; Poutrel et al., 1988). Since purified CP5 and CP8 demonstrated only weak immuno-
genicity in mice, purified CPs were conjugated to a non-toxic variant of Exotoxin A (ETA) of
Pseudomonas aeruginosa to increase immunogenicity. The conjugate induced high titres of
CP-specific antibodies and a T-cell dependent immune response (Fattom et al., 1990). Fur-
thermore, active immunisation using a bivalent CP5-CP8 conjugate vaccine (StaphVaxTM;
Nabi Biopharmaceuticals) led to an increased survival rate in mice (Fattom et al., 2004),
but failed to pass the Phase III clinical trial in end stage renal disease patients. A sec-
ond Phase III trial in haemodialysis patients also failed, hence halting the development of
StaphVax (Garcia-Lara and Foster, 2009). Currently a combined vaccine including CP5,
CP8, polysaccharide component 336 and two staphylococcal toxins is under investigation
(Pentastaph; http://www.nabi.com).
The polysaccharide intercellular adhesin of S. aureus and S. epidermidis is a poly-N-
acetylglucosamine (PNAG) that enables adhesion to inert surfaces and living tissues. Im-
munisation using PNAG achieved moderate protection in rabbit models of endocarditis or
catheter-associated bacteraemia and a murine model of kidney infection (Maira-Litran et al.,
2004).
Also secreted extracellular molecules like TSST-1 have been tested in immunisation
studies. For this purpose either a non-toxic mutant or formaldehyde inactivated TSST-1
was used for vaccination of rabbits and achieved a protection from lethal challenge with
S. aureus (Hu et al., 2003). However, due to the high variability in the set of toxin genes
and their expression between different S. aureus strains, toxins alone are most likely no
promising vaccine target.
Due to their function and surface localisation cell wall associated proteins represent
promising targets. To date several cell wall anchored proteins harbouring the LPXTG motive
have been tested in immunisation studies. For example, improved survival of mice was ob-
served upon immunisation with the collagen binding protein (Cna) in a murine model of sep-
sis (Nilsson et al., 1998). However, as Cna is not present in all S. aureus strains, it is not el-
igible as single component vaccine. In another attempt immunisation with IsdA, IsdB, SdrD
11
2 Introduction
or SdrE significantly reduced the bacterial load in infected kidneys (Stranger-Jones et al.,
2006). Moreover, as observed in the same study immunisation with a multicomponent vac-
cine consisting of IsdA, IsdB, SdrD, and SdrE induced opsonophagocytic antibodies against
each component in immunised mice, reduced the load of S. aureus in kidneys and improved
survival upon lethal challenge with S. aureus. The iron surface determinant B (IsdB) is also
the basis of Merck’s V710 vaccine (Garcia-Lara and Foster, 2009), for which a Phase II clini-
cal trial has just been completed (Feb 2010; http://clinicaltrials.gov/ct2/show/NCT00572910).
Immunisation with IsdA and Clumping factor B (ClfB), two major determinants in nasal car-
riage, decreased nasal colonisation in a cotton rat and murine model of nasal carriage,
respectively (Clarke et al., 2006; Schaffer et al., 2006). Thereby representing a potential
option to restrict the spread of CA-MRSA.
Altogether, much effort has been made to characterise potential vaccine candidates in
in vivo infection models and some promising results have been achieved. But these re-
sults, especially those already tested in clinical trials, strongly suggest that due to the high
variability in the spectrum of virulence factors for each strain as well as the redundancy
in protein function, a single component vaccine will not be sufficient to confer protection.
The results obtained by Stranger-Jones et al. (2006) point towards a polyvalent vaccine as
the most promising strategy to combat S. aureus infections. Thus, the identification and
characterisation of eligible candidates is pivotal for the development of a successful multi-
component vaccine. In this regard ACW proteins of S. aureus represent a new interesting
class of vaccine candidates, since they exhibit both important enzymatic function and sur-
face localisation.
2.3.2 Passive immunisation
Since active immunisation will most likely require a booster immunisation to achieve full
protection, it is not representing a treatment option for already infected patients or patients
short before surgery. In these cases, passive immunisation might represent an interesting
alternative. Especially, as it is also applicable in immunocompromised patients, not able to
trigger a sufficient humoral response upon active immunisation.
In the pre-antibiotic era the so-called serum therapy represented the first attempt of pas-
sive immunisation to overcome infections (Casadevall and Scharff, 1994). Although effec-
tive, it caused severe side effects, due to poor purity of the antibody fractions used. Since
then antibody purification methods have vastly improved, thereby circumventing adverse
effects due to impurities. For example intravenous immunoglobulin preparations (IVIG) de-
rived from human plasma are routinely used in immunocompromised patients to provide
antibodies against various pathogens and thereby support the immune system.
Several attempts have been made to test for protective effects by passive immunisation
against different target molecules. For example a hyperimmune polyclonal immunoglobulin
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preparation targeting CP5 and CP8 obtained from volunteers immunised with StaphVaxTM
(Altastaph; Nabi Biopharmaceuticals) failed to prove efficacy in two Phase II clinical trials
(Benjamin et al., 2006; Rupp et al., 2007).
Biosynexus has developed a humanised mouse chimeric IgG1 monoclonal antibody with
in vitro opsonophagocytosis activity to S. epidermidis lipoteichoic acid (LTA), a membrane
bound glycolipid extending into the cell wall of gram-positive bacteria (Pagibaximab). It
conferred around 80 % protection against lethal challenge with S. aureus in rodent models
(Weisman, 2007), and Phase I/II clinical trials in low birth weight (LBW) neonates demon-
strated that it is non-immunogenic, opsonic against coagulase negative S. aureus and re-
duces the incidence of bacteraemia (Weisman et al., 2009).
Another target under investigation is clumping factor A (ClfA), which belongs to the family
of MSCRAMMs. ClfA mediates adhesion by binding to host ligands like fibrinogen and was
previously shown to be required for virulence in a murine septic arthritis model (Josefsson
et al., 2001). Passive immunisation with either rat or rabbit anti-ClfA polyclonal antibodies
conferred protection in murine models of sepsis and arthritis. Veronate ® (Inhibitex) is a
human immunoglobulin preparation from plasma donors with naturally occurring high titres
of IgG to ClfA and to the S. epidermidis fibrinogen binding protein (SdrG). Although protec-
tive in animal models (Vernachio et al., 2006), it failed to meet its primary endpoint, a 50 %
reduction in late onset S. aureus bacteraemia, in a Phase III clinical trial in LBW neonates
(DeJonge et al., 2007).
These results further underline the necessity of the identification of S. aureus protein can-
didates conferring protection by either active or passive immunisation, as components of a
polyvalent vaccine against S. aureus. The major advantage of passive immunisation is the
option to combine antibodies against multiple targets exhibiting different functions, e.g. neu-
tralisation of bacterial toxins and opsonisation for subsequent elimination by professional
phagocytes, thereby further increasing the protective potential of a polyvalent vaccine.
2.3.3 Antibacterial function of immunoglobulins
The main antibacterial functions of immunoglobulins are 1) opsonisation and in turn Fc
γ-receptor mediated phagocytosis by professional phagocytes such as neutrophils or ma-
crophages, 2) the neutralisation of adhesion to host cell tissue by binding to the respective
pathogen associated protein, and 3) neutralisation of bacterial toxins. Besides, immune
complexes of antibodies and toxins, which are not sufficient to induce Fc γ-receptor de-
pendent uptake by phagocytes, are eliminated by activation of the classical pathway of
complement activation. Additionally, antibodies have also been shown to amplify or sup-
press the inflammatory response depending on their specificity, isotype and concentration
(Casadevall and Pirofski, 2003).
Apart from this indirect antimicrobial activities, there are some examples for direct an-
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timicrobial actions mediated by antibodies. It was shown that IgM or IgG specific for Bor-
relia burgdorferi surface proteins damage the surface protein coat of the organism, thereby
leading to a bactericidal effect in the absence of complement (Connolly and Benach, 2001;
Connolly et al., 2004). Furthermore, an antibody specific for Escherichia coli LPS was found
to be bacteriostatic due to interference with the release of an iron chelator (enterochelin),
thus preventing iron uptake (Fitzgerald and Rogers, 1980). Similarly, IgM monoclonal an-
tibodies specific for surface proteins of Acinetobacter baumanii have been reported to be
bactericidal by inhibition of iron uptake (Goel and Kapil, 2001).
In 1971 it was reported that human serum exhibits a bacteriostatic effect on S. aureus
(Ehrenkranz et al., 1971). The underlying mechanism is not yet described, but an antibody
directly inhibiting the growth S. aureus would be of great benefit in the context of passive
immunisation.
2.4 Aim of the study
Due to the worldwide increasing prevalence of S. aureus resistant to multiple antibiotics
(MRSA) in both hospital and community as well as the rapid emergence of resistances
against new antibiotics, the development of alternative strategies for the treatment and pre-
vention of staphylococcal infections is essential. Because S. aureus infections always de-
pend on a multitude of virulence factors and there is a high variability in virulence factor
genes among S. aureus isolates, single target strategies are less promising. Furthermore,
passive immunisation strategies are particularly advantageous, due to their short term ap-
plicability and potential composition of immunoglobulins of different isotypes and function-
alities.
The aim of this study was to investigate a potential bacteriostatic effect on S. aureus con-
ferred by specific IgGs, using an intravenous immunoglobulin (IVIG) preparation as source
of naturally occurring, S. aureus specific IgGs. Due to the enormous potential of a direct
bacteriostatic effect elicited by IgGs for passive immunisation, the mechanism underlying
bacteriostasis was analysed by gene expression profiling during inhibition of growth.
Additionally, this study aimed to enlarge the pool of potential candidates for a polyvalent
vaccine. Thus, immunogenic anchorless cell wall proteins of S. aureus were identified and
characterised regarding their potential to confer protection against lethal challenge with
S. aureus upon active immunisation in a murine model of sepsis.
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3.1 Material
3.1.1 Chemicals and enzymes
Chemicals were of research grade and purchased from AppliChem, Merck, Sigma-Aldrich,
ROTH or Becton Dickinson GmbH unless stated otherwise. Buffers and solutions were
obtained from Bio-Rad or prepared using bi-distilled H2O from an EASYpure UV/UF H2O
purification unit (Werner Reinstwassersysteme), degassed and sterilised by autoclaving or
filtration through a 0.2 µm membrane, if necessary. Restriction enzymes were obtained
from Fermentas and used in recommended buffers. PFU Polymerase was obtained from
Promega and recombinant Lysostaphin from Sigma-Aldrich.
3.1.2 Bacteria and culture media
E. Coli Genotype Provider
E. coli K12 XL1Blue
recA1 endA1 gyrA96 thi-1 hsdR17
StratagenesupE44 relA1 lac [F’ proAB lacIqZ∆M15
Tn10 (Tet,r)]
DH5α
F-φ80dlacZ∆M15∆(lacZYA-argF)U169
InvitrogenrecA1 endA1 tonA hsdR17(rK- mK+)
phoA supE44 λ -thi-1 gyrA96 relA1
BL 21 F- dcm ompT hsdS (rB- mB-) gal Stratagene
S. aureus Resistance Provider
ATCC 29213 MSSA American Type Culture Collection
ATCC 29213-GFP
Ampicillin/ Inst. for Med. Microbiology,
Chloramphenicol Immunology and Hygiene, S. Leggio
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Media / Antibiotics Composition
LB -Medium 1 % Tryptone; 0.5 % Yeast extract; 0.5 % NaCl; pH 7.0
LB-Agar
1 % Tryptone; 0.5 % Yeast extract; 0.5 % NaCl,
15 % Agar; pH 7.0
SOC-Medium
2 % Tryptone, 0.5 % Yeast extract,
0.5 % NaCl, 25 mM KCl,
100 mM MgCl2, 20 mM Glucose; pH 7.0
Ampicillin
Stock solution: 50 mg/ml in H2O
Working concentration: 50 µg/ml
Chloramphenicol
Stock solution: 10 mg/ml in MeOH
Working concentration: 20 µg/ml
Kanamycin
Stock solution: 50 mg/ml in H2O
Working concentration: 50 µg/ml
3.1.3 Buffers and solutions
Buffers and Solutions Composition
cDNA labelling
50 x aa-dNTP Mix
25 mM dATP, 25 mM dGTP, 25 mM dCTP,
15 mM dTTP, 10 mM aminoally-dUTP
1M Phosphate buffer 9.5 ml 1M K2HPO4 , 0.5 ml 1M KH2PO4; pH 8.5-8.7
Phosphate wash buffer 5 mM Phosphate buffer in 80 % Ethanol; pH 8.0
Phosphate elution buffer 4 mM Phosphate buffer; pH 8.0
Dye coupling buffer 100 mM Na2CO3; pH 9.0 (freshly prepared)
Cy-Dyes content of one vial reconstituted in 73 µl DMSO,
(GE Healthcare) stored dessicated at -20 ° C
Stop solution
100 mM NaOAc; pH 5.2
(Dye coupling)
Microarray hybridisation
20x SSC 3 M NaCl, 0.3 M Natriumcitrate; pH 7.0
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Buffers and Solutions Composition
10 % SDS 100 g SDS in 1000 ml A. bidest.
Prehybridisation 3.5 x SSC, 0.1 % SDS, 10 mg/ml BSA in A. bidest
Wash A 1 x SSC, 0.05 % SDS
Wash B 0.06 x SSC
Agarose gels
50 x TAE buffer
40 mM Tris, 20 mM Acetic acid,
2 mM Na2EDTA, pH 8.5
10 x Loading buffer
200 mM Tris-Acetat, 5 mM Na2EDTA,
0,01 % Bromphenolblue, 50 % Glycerin (v/v),
pH 8.0 at 37 ° C for 3 h stirring
1 Kb DNA-ladder
100 µl 1 Kb Plus DNA-Ladder (Invitrogen),
400 µl 10 x loading buffer, 500 µl A. bidest
1% Agarosegel
1 g Agarose, 100 ml 1x TAE-Puffer,
1 µl Ethidiumbromid (10 µg/µl)
1D- and 2D-SDS-PAGE
10 x Laemmli buffer
0.06 M Tris-HCl (pH 6.8), 2 % SDS, 25% Glycerol,
0.2 % Bromphenolblue, 10 % 2β-Mercaptoethanol
Rehydration solution
8 M Urea, 2 M Thiourea, 40 mM DTT, 1 % CHAPS,
0.5 % Pharmalyte
Equilibration solution
50 mM Tris-HCL (pH 8.8), 8 M Urea, 2 M Thiourea,
30 % Glycerol, 2 % SDS, 0.05 % Bromphenolblue
TT buffer 3M Tris-HCl, 0,3 % SDS, 1 mM EDTA; pH 8.5
TE buffer 10 mM Tris/HCl, 1 mM EDTA; pH 8.0
Silver staining
Fixation solution 50 % EtOH, 10 % Acetic acid
Incubation solution
30 % EtOH, 6.8 % NaOAc, 0.5 % Glutaraldehyde,
0.2 % Na2S2O3 x 5 H2O
Staining solution 0.1 % AgNO3, 0.02 % Formaldehyde
Developing solution 2.5 % Na2CO3, 0.01 % Formaldehyde
Stop solution 5 % Acetic acid
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Buffers and Solutions Composition
Coomassie staining
Staining solution 2.5 % Serva blue R250, 45 % Ethanol, 15 % Acetic acid
De-colourisation solution 45 % Methanol, 15 % Acetic acid
Immunoblotting
TBST buffer (10x) 1.5 M NaCl, 0.5 M Tris, 0.5 % Tween 20, pH 7.4
PBST buffer (10x)
1.4 M NaCl, 27 mM KCl, 100 mM NaH2PO4,
18 mM KH2PO4, 0.2% Tween 20; pH 7.4
Blocking buffer 5 % skim milk powder, 2 % BSA in 1x TBST
Transfer buffer 25 mM Tris-HCl, 192 mM Glycine, 20 % Methanol
Stripping buffer
62.5 mM Tris-HCl, 2 % SDS,
100 mM 2β-Mercaptoethanol; pH 6.8
Colony Blot
Denaturing solution 0.5 M NaOH, 1.5 M NaCl
Neutralisation solution 1.5 M NaCl, 0.5 M Tris-HCl; pH 7.4
20 x SSC 3 M NaCl, 0.3 M sodium citrate; pH 7.0
Affinity chromatography
Recombinant proteins
10 x PBS
1.4 M NaCl 100 mM Na2PO4, 27 mM KCl,
18 mM KH2PO4; pH 7.4
Resuspension buffer
1 x PBS, 500 mM NaCl, 5 % Glycerol,
EDTA-free complete protease inhibitor
Binding buffer 1 x PBS, 500 mM NaCl, 40 mM Imidazole; pH 7.4
Elution buffer 1 x PBS, 500 mM NaCl, 250 mM Imidazole; pH 7.4
Dialysis buffer 1 x PBS, 10 % Glycerol; pH 7.4
Antibody enrichment
Wash A (NHS column) 0.5 M Ethanolamine, 0.5 M NaCl; pH 8.3
Wash B (NHS column) 0.1 M NaOAc, 0.5 M NaCl; pH 4.0
Storage buffer 0.05 M Na2HPO4, 0.1 % NaN3; pH 7.0
1 x PBS 140 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4,
(binding buffer) 1.8 mM KH2PO4; pH 7.4
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Buffers and Solutions Composition
Elution buffer 0.1 M Glycine-HCl; pH 2.5
Neutralisation buffer 1 M Tris-HCl; pH 9.0
3.1.4 Technical equipment
Device Specification Provider
Centrifuge Megafuge 1.0 R Thermo Scientific
Colony counter Countermat FLASH IUL
Developer AGFA Curix 60 AGFA
Electrophoresis chamber Criterion Cell Bio-Rad
Electrophoresis chamber Ettan Dalt II System GE Healthcare
ELISA-Reader MRX Tc Dynex Technologies
Flow cytometer FACScalibur BD Biosciences
FPLC system ÄKTATM Purifier GE Healthcare
French® Press Cell K20, 20000 PSI Thermo Scientific
French pressure cell press French® Press Thermo Scientific
Gel documentation Gel Doc 2000 Bio-Rad
High-speed centrifuge RC 5 C plus Sorvall
IEF Multiphor II GE Healthcare
Incubator (bacteria) Kelvitron t Thermo Scientific
Incubator (cells) Hera Cell 240 Thermo Scientific
Lightcycler® Lightcycler® LC480 Roche
MALDI-TOF MS Reflex IV Bruker Daltonics
Microarray scanner Axon GenePix 4100 Axon Instruments
Microcentrifuge Centrifuge 5417 R Eppendorf
Microscope Axiovert 25 Zeiss
PCR cycler Thermocycler T3 Biometra
Power supply Power Pac 3000 Bio-Rad
Power supply for Multiphor II EPS-3501xL GE Healthcare
Roller-mixer Cat RM5 Zipperer
Spectrophotometer Genesis 20 Thermo Scientific
Spiral plater Eddy Jet IUL
Tank-Blotter Criterion blotter (9.4x15 cm) Bio-Rad
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Device Specification Provider
Tank-Blotter Trans-Blot cell (16x20 cm) Bio-Rad
Test-Tube-Rotator Model 34528 Snjiders
Thermomixer Comfort Eppendorf
3.1.5 Consumables
Designation Manufacturer
Bottle-Top-Filter PES, 0.45 µm Nalgene
Centricon-Plus 70, 30 000 MWCO Millipore
Corning hybridisation chambers Corning
CriterionTM Empty Cassettes Bio-Rad
Amersham Hyperfilm ECL GE Healthcare
Eddy-Jet tips IUL
HiPrepTM 26/10 Desalting Column GE Healthcare
HisTrapTM FF crude Columns GE Healthcare
HiTrapTM NHS-activated HP Columns GE Healthcare
IEF-Electrode Strips GE Healthcare
ImmobilineTM Dry Strips (3-10NL/4-7 NL) GE Healthcare
LifterslipsTM22 x 22 1 mm Implen
LightCycler® 480 Multiwell Plate 96, white Roche
MaxisorpTM flat-bottom 96-well plate Nunc
Mueller-Hinton Agarplatten Oxoid
Nitrocellulose Schleicher & Schuell
Sterifix® Injection Filter, 0.2 µm Braun
3.1.6 Kits
Designation Manufacturer
DC-Protein Assay Bio-Rad
AmershamTM ECLTM Detection Reagent GE Healthcare
Ettan Dalt II Gel and Buffer Kit GE Healthcare
LightCycler® 480 SYBR Green I Master Roche
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Designation Manufacturer
QIAprep Spin Miniprep Qiagen
QIAquick PCR Purification Qiagen
RNeasy Mini Kit Qiagen
Superscript® III first strand synthesis system Invitrogen
OptiEIATM TMB Substrate Reagent Set BD Biosciences
3.1.7 Oligonucleotides
Desalted oligonucleotides were obtained from Operon and a 100 µM stock-solution ( TE;
pH 8.0) was prepared and stored at -20 ° C. Primers were used in a final concentration of
5 pmol/µl for cloning of the vaccine candidates or 10 pmol/µl for qPCR, respectively.
Gene Name Sequence (5’ to 3’)
BT1 BT1-f CCA TGG CTA AAT CAG TGG CTA
BT1-r AAC CTC GAG CAA CTC TGC GAT TAC
BT2 BT2-f GTT CCA TGG GTC ATC AAG CAG ATG
BT2-r GTG CTC GAG TCT ACT TTG CAA GTA
BT3 BT3-f CCA TGG GAA CAC CAA TTA TAG C
BT3-r GCC CTC GAG TTT TGC ACC TTC TAA
qPCR 16SrRNA
16S-f TCG GGG GAC AAA GTG ACA GGT
16S-r AGA GTG CCC AAC TTA ATG ATG GC
qPCR fur
fur-f GTT ACC AGA AGT TGA AAA TCG AGT TGA
fur-r CTA TCC TTT ACC TTT AGC TTG GCA CG
qPCR fhuC
fhuC-f ACC TGA AGT AGC AGA TGG CTT AAC TG
fhuC-r CCA ATC AAT TTC TTT CTT ATC CTC AGC
qPCR fhuD2
fhuD2-f AGC AAT TGG ACA AGA TGC AAC AGT
fhuD2-r ATG CTT GAT ATA ATA CTT CTC CAC CAC G
qPCR ribA
ribA-f GAT TGT GGT GCT CAA CTT GAA TCG
ribA-r ATT TGT TTA ACA ATC CTA TGC CAC GAC
qPCR catalase
cata-f ATA TTC TCT GAA ATA GGT AAG CAA ACC G
cata-r TTA ACG CAA ATC CTC GAA TGT CAC
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Gene Name Sequence (5’ to 3’)
qPCR ferritin
ferri-f CAG CAC CAA AAA TTG ACT TTT CAA G
ferri-r TCT TGA CGA GCG ATT TCA GAT AAG TTA
3.1.8 Antibodies
Antibody Characteristics Provider
Octagam® (IVIG)
Intravenous immunoglobulin preparation Octapharma
1:500
Venimmun® N (IVIG)
Intravenous immunoglobulin preparation Aventis Behring
1:500
Anti-6-His-tag
monoclonal mouse anti 6-His-tag clone 13/45/31 Dianova
1:5000
Anti-human IgG
Polyclonal HRP-goat anti-human IgG Sigma
1:2500
Anti-human FCγ
Polyclonal PE-goat anti-human FCγ F(ab)2 Dianova1:100
Anti-mouse IgG
Polyclonal HRP-goat anti-mouse IgG Sigma
1:5000
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3.2 Methods
3.2.1 Depletion of specific IgGs from IVIG
S. aureus ATCC 29213 or E coli K12 XL1blue from an overnight (ON) culture was inocu-
lated 1:100 in 400 ml LB and cultured until an optical density of 2.0 at 600 nm (OD600) was
reached. Subsequently bacteria were harvested by centrifugation, washed in phosphate-
buffered saline (PBS) (pH 7.3) and resuspended in an IVIG preparation (Octagam ®, Oc-
tapharma) or PBS as control. The suspension was rotated slowly ON at 4 ° C, subsequently
bacteria were removed by centrifugation, and the supernatant was sterile filtered through a
0.2 µm membrane filter. Protein concentration of IVIG depleted of S. aureus (dSaIVIG) or
E. coli specific IgGs (dEcIVIG) was determined using the Bio-RAD DC assay according to
the manufacturer’s instructions.
3.2.2 S. aureus growth curves
S. aureus ATCC 29213 from ON culture was inoculated 1:100 into LB broth and cultured
until OD600 of 0.3 was reached. Subsequently bacteria were harvested by centrifugation at
4 ° C, 3000 g for 15 minutes. After washing once with cold PBS, the number of S. aureus
colony forming units (CFU) was estimated by OD measurement, based on the observation
that an OD 600 of 3 equates to 1 x 109 CFU/ml. For experimental assays 1 x 104 CFU were
inoculated in 500 µl LB broth. 13 mg / ml of either IVIG, BSA, dialysed IVIG (IVIG-DS),
dSaIVIG or dEcIVIG adjusted in 500 µl PBS or solely PBS were added (final volume =
1 ml). Where indicated 25 or 50 % of the total volume (1 ml) were substituted by human
serum, heat-inactivated (HI) human serum, IVIG or PBS (control). At defined time points
(every hour up to 5 hours) samples were taken, diluted 1:2 in 0.1 % Triton X 100, sonicated
for 5 minutes and 50 µl of suitable dilutions were plated on Mueller Hinton agar using the
Eddy jet spiral plater (IUL Instruments). Plates were incubated at 37 ° C for 16 hours and
CFUs were enumerated using the Countermat Flash (IUL Instruments). Experiments were
performed using triplicates.
To enable expression profiling during the course of growth inhibition, RNA was isolated
from S. aureus cultured in the presence of IVIG, dSaIVIG or PBS. In a total volume of 10 ml,
1 x 107 CFU / ml were co-incubated with either 2.5 mg / ml IVIG, dSaIVIG or PBS substituted
with 5 mg / ml Maltose (adjusted to the concentration present in IVIG) in a 1:1 ratio with LB
broth. To assess growth of S. aureus under these conditions, triplicate samples for each
treatment were included in parallel to the samples for RNA isolation. At defined time points
(every 30 minutes up to 120 minutes, or immediately before RNA isolation) a sample was
taken, diluted 1:2 in 0.1 % Triton X 100, sonicated for 5 minutes and 50 µl of suitable dilutions
were spirally plated on Mueller Hinton agar. Plates were incubated at OD 37 ° C for 16 hours
and CFUs were enumerated. RNA samples were immediately harvested by centrifugation
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and the pellets washed once with ice-cold TE pH 8.0, and immediately subjected to RNA
isolation
3.2.3 RNA isolation
Subsequent to washing with ice cold TE pH 8.0 bacterial pellets were resuspended in 100 µl
of 0.5 µg / µl Lysostaphin-TE (pH 8.0) and incubated for 20 minutes at RT, followed by Pro-
teinase K treatment for 20 minutes at RT. Subsequently 350 µl RLT buffer containing β
-Mercaptoethanol was added and samples stored at -80 ° C until RNA cleanup using the
RNeasy ® Mini kit (Qiagen) according to the manufacturer’s instructions. To degrade ge-
nomic DNA an on column DNA digestion was included as recommended by the manufac-
turer. Concentration and purity of RNA diluted in 10 mM Tris pH 7.5 was determined by
spectrophotometry. Only RNA samples with an A 260 /A280 ratio of 1.9 to 2.1 were used for
expression profiling. Until use RNA was stored at -80 ° C.
3.2.4 Synthesis and labelling of cDNA
For use in quantitative realtime PCR (qPCR) 2 µg total RNA was reverse transcribed into
cDNA using the Superscript® III Kit (Invitrogen) using random hexamers according to the
manufacturer’s instructions. To account for variability in cDNA synthesis, each target RNA
was reverse transcribed in triplicates. Absence of contaminating genomic DNA was con-
firmed by analysis of samples without reverse transcriptase (-RT samples).
For subsequent microarray hybridisation samples were indirectly labelled by incorpora-
tion of amino-allyl(aa)-dUTPs during cDNA synthesis, using a protocol developed by the in-
stitute for genomic research (TIGR) with modifications. 5 µg total RNA were mixed with 6 µg
random hexamers adjusted to a volume of 14 µl DEPC-H2O and incubated for 10 minutes
at 70 ° C (denaturation), subsequently chilled on ice for one minute and briefly centrifuged.
Then 50 x aa-dNTP mix was added to achieve a final concentration of 0.5 mM for dATP,
dCTP and dGTP, or 0.3 mM dTTP and 0.2 mM aa-dUTP, respectively in 30 µl reaction vol-
ume. The other components (10 x RT buffer, 25 mM MgCl2, DTT and RNaseOut
®) provided
by the superscriptIII ® Kit were added accordingly. Upon addition of 2 µl reverse transcrip-
tase (superscript® III) samples were incubated for 30 minutes at 25 ° C, followed by ON
incubation at 42 ° C. Subsequently samples were incubated for 5 minutes at 85 ° C, followed
by addition of RNaseH and further incubation for 20 minutes at 37 ° C. Prior to labelling
cDNA samples were purified using the QiaQuick ® PCR purification kit (Qiagen) according
to the manufacturer’s instructions with freshly prepared phosphate wash buffer instead of
PE-wash buffer. The cDNA was eluted twice with 30 µl Phosphate elution buffer, followed by
drying using the speedvac. Cy-3 and Cy-5 dye esters were reconstituted as recommended
by the manufacturer (GE-Healthcare) and 4.5 µl were added to cDNA, resuspended in 4.5 µl
freshly prepared 0.1 M Na2CO3 pH 9.0, followed by incubation for 1 hour at RT in the dark.
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The Dye-coupling reaction was stopped by addition of 35 µl 100 mM NaOAc pH 5.2. Sam-
ples intended for co-hybridisation were mixed and subjected to QiaQuick ® PCR purification
according to the manufacturer’s instructions. Mixed labelled cDNA was eluted in 30 µl H2O
and immediately used for microarray hybridisation.
3.2.5 Hybridisation of microarrays
Microarray slides derived from the Bacterial Microarray Group at Saint Georges (BµG@S)
were pre-hybridised in a coplin jar at 65 ° C in 50 ml of prewarmed pre-hybridisation so-
lution for 20 minutes, followed by a 1 minute wash in H2O and a final rinse in isopropyl
alcohol. Pre-hybridised microarray slides were immediately dried by centrifugation at 425 g
for 5 minutes as recommended by BµG@S. Upon elution from QiaQuick columns labelled
cDNA was adjusted to a final concentration of 4 x SSC and 0.3 % SDS in a total volume
of 45 µl by addition of 20 x SSC and 2 % SDS. Samples were incubated for 2 minutes at
95 ° C, allowed to chill slightly followed by brief centrifugation. Pre-hybridised microarray
slides were placed in Corning hybridisation chambers (Corning) and the LifterSlipsTM (Im-
plen) were carefully aligned, to cover the spotted area, then the sample was applied and
moved by capillary action to the end of the LifterSlipTM. To prevent slides from drying, 15 µl
H2O were applied to each of the two wells in the chamber, then chambers were sealed and
submerged in a waterbath at 65 ° C for 18 hours. After incubation LifterSlipsTM were re-
moved and slides were washed twice in pre-heated wash solution A at 65 ° C for 2 minutes,
followed by washing twice in wash solution B under same conditions. Slides were dried by
centrifugation and kept dry in the dark until scanning.
Samples derived from co-incubation with IVIG were labelled with Cy5 and were co-
hybridised either with Cy3-labelled PBS or dSaIVIG treated samples. Four biological repli-
cates for each comparison per time point (t0, t30 and t60) were analysed. To assess Dye-
dependent variability, a Dye-swap experiment was performed.
3.2.6 Analyses of microarrays
Microarray slides were scanned using the Axon 4100 Scanner and GenepixPro 6.1 Soft-
ware (Molecular Devices). The PMT gain for each dye (Cy3/Cy5) was adjusted to fulfil
two criteria: 1) max 0.05 % saturated pixels and 2) an overall intensity ratio of both dyes
close to 1. Slides were scanned with a pixel size of 10 µm and averaging the signals upon
scanning each line three times. Subsequent to scanning the grid that links spot-location
to gene annotation was aligned carefully with the spotted area and the respective spots.
When each spot was correctly aligned, analysis was performed and the raw data were ex-
ported to an Acuity (Molecular Devices) database for normalisation and post-analysis. In
Acuity all arrays were first normalised using LOWESS normalisation followed by creating
data sets for each time point (t0, t30 and t60) and co-hybridisation (IVIG vs. dSaIVIG; IVIG
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vs. PBS). Recommended settings for filtering criteria were applied to exclude signals from
the dataset, which are not exceeding background or signal to noise ratio levels lower than
3. Genes not showing a fold change of about 1.5 in three of the four arrays in a dataset
were excluded from further analysis. The remaining dataset was then statistically analysed
using student’s t-test including Benjamini-Hochberg correction (Benjamini and Hochberg,
1995) of resulting p-values. Candidate genes identified with a p-value less than 0.05, were
distributed into functional groups following gene annotation and blast analysis against all
completely sequenced S. aureus genomes.
3.2.7 Quantitative realtime PCR (qPCR)
The expression changes of selected genes identified by microarray analysis were validated
by qPCR using the LightCycler ® LC480 (Roche). As housekeeping gene 16 S rRNA was
used. For qPCR 1 µl of a 1:4 dilution of each target-cDNA was used in a total reaction vol-
ume of 20 µl, containing primers, 2× LightCycler ® 480 SYBR green I mastermix adjusted
with nuclease free water. Primers were used at a final concentration of 10 pmol.
qPCR program:
Step of program Temperature Duration
Initial denaturing 95 ° C 15 min.
Cyclic denaturing 95 ° C 15 sec.
Annealing 55 ° C 20 sec.
 45×Elongation 72 ° C 20 sec.
Melting curve from 50 ° C to 95 ° C 1 ° C/sec.
Due to differences in the qPCR efficiencies between target and reference (16 S rRNA)
genes the ∆∆ ct method could not be used for analysis of the qPCR data. Therefore, a
standard curve was determined for all primer pairs, by measurement of 2 x serial dilutions
of control (PBS, t0) cDNA and included in each run, to enable quantification. Values were
normalised to 16 S rRNA and mean and SD of triplicates was calculated.
3.2.8 Isolation of S. aureus anchorless cell wall (ACW) proteins
S. aureus ATCC 29213 from ON culture was inoculated into LB broth adjusting to a starting
OD600 of 0.05. Bacteria were cultured until early exponential growth phase. ACW proteins
were extracted from bacterial pellets using a modified protocol of a previously described
method (Antelmann et al., 2002). The pellets were extensively washed, resuspended in
1.5 M LiCl, 25 mM Tris-HCl (pH 7.2) containing complete protease inhibitors, and incubated
on ice for 30 min. Subsequent to centrifugation, the supernatants were pooled and preci-
pitated with 10 % (w/v) trichloroacetic acid ON at 4 ° C. The precipitate was washed thrice
with ice-cold ethanol and dried under vacuum. Extracted proteins were dissolved in 8 M
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urea for 2-D gel electrophoresis (2-DE). Protein concentration was determined using the
Bio-Rad DC assay in a 1:4 dilution according to the manufacturer’s instructions.
3.2.9 Subtractive proteome analysis (SUPRA)
2-DE was performed according to the method described by Bernardo et al. (2004) using
the Multiphor II system according to the manufacturer’s instructions. Proteins dissolved in
8 M urea were separated on 18-cm immobilised pH gradient (IPG) strips using non-linear
pH ranges of 3 to 10 and 4 to 7 (GE Healthcare). Isoelectric focusing was performed using
500 µg protein for Coomassie blue-stained gels and Western blots and 100 µg for silver-
stained gels and Western blots. S. aureus ACW-proteins were then separated on 12.5 %
Tris-glycine-SDS gels (25 cm by 20 cm by 1.0 mm) using the Ettan Dalt II system (GE
Healthcare).
For immunoblotting, proteins separated by 2-DE were transferred to nitrocellulose mem-
branes using a Trans-Blot cell (Bio-Rad) according to the manufacturer’s instructions. Mem-
branes were probed ON at 4 ° C either with IVIG at a dilution of 1:500 or with IVIG de-
pleted of S. aureus specific IgGs (dSaIVIG) using an equivalent antibody concentration.
Specific detection of immune complexes was performed using anti-human IgG-HRP con-
jugated secondary antibody at a 1:2,500 dilution. After treatment with dSaIVIG the mem-
brane was stripped at 50 ° C using stripping buffer containing 62.5 mM Tris-HCl (pH 6.8),
2 % SDS, and 100 mM β -mercaptoethanol and incubated with IVIG. To assess the repro-
ducibility of spot patterns, three separate experiments were performed. Signals of interest
were matched with corresponding spots on the Coomassie stained preparative gel, excised,
and digested with trypsin, followed by matrix-assisted laser desorption ionisation - time of
flight (MALDI-TOF) mass spectrometry performed as previously described (Bernardo et al.,
2004). Probability-based scoring (probability based on implementation of the Mowse algo-
rithm for assessing peptide and protein matches (Pappin et al., 1993)) was performed by
using the equation -10 x log(P), where P is the probability that the observed peptide match
is a random event. Scores greater than 56 were considered significant.
3.2.10 Cloning, expression and purification of vaccine candidates
The ORFs encoding BT1, BT2 and BT3, lacking potential secretion signalling sequences,
were amplified from S. aureus ATCC 29213 genomic DNA by PCR using Pfu-Polymerase.
The PCR products were purified using the QiaQuick PCR purification kit according to the
manufacturer’s instructions. PCR product and dephosphorylated pET29b vector were re-
stricted using NcoI and XhoI in 2x Tango buffer for 2 hours at 37 ° C, subsequently ligated
and transformed into E. coli DH5 α and selected on Kanamycin-LB plates. Vector pET29b
provides a N-terminal S-tag and a C-terminal His-tag in frame with the inserted gene. Cor-
rect constructs, identified by colony PCR and restriction analysis, were sequenced and
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transformed into E. coli BL 21 for protein expression.
Clones with the highest efficiency in the expression of the respective fusion proteins were
identified by colony blot analysis. Briefly, the colonies from transformation plates after ON
incubation were transferred to a fresh plate containing 1 mM IPTG by nitrocellulose filters
with colonies side up. After incubation of these plates for 4 hours at 37 ° C, filters were
placed colony side up on Whatman paper soaked with 10 % SDS for 10 minutes, then
filters were placed on paper soaked with denaturing solution for 5 minutes. Filters were
subsequently incubated twice for 5 minutes on neutralising solution, and finally for 15 min-
utes on 20 x SSC followed by two 5 minute washes in 1 x TBST. Finally membrane filters
were blocked for 30 minutes at RT and subsequently incubated with anti-His primary an-
tibody ON at 4 ° C. Prior to and after incubation with HRP-conjugated secondary antibody
membranes were washed thrice in 1 x TBST, then treated with ECL reagent. Exposed films
were developed, detected colonies aligned with original colonies on transformation plates
and selected colonies were used for preparation of glycerol stocks for further use. Expres-
sion clones from ON culture in Kanamycin-LB were inoculated 1:100 in 400 ml Kanamycin-
LB and cultured until an OD 600 of 0.6. Then IPTG (final concentration 1 mM) was added
and incubated for 4 hours. Bacteria were harvested, washed twice in PBS and stored in
1 x PBS buffer containing EDTA-free complete protease inhibitor (Roche), 5 % Glycerol and
LysonaseTM at -20 ° C until lysis of the cells by French Press. Upon disruption of the cells
by French press with a pressure of 20 000 PSI cell debris was eliminated by centrifugation
at 17000 g.
Prior to loading onto equilibrated HisTrapTMFF crude columns (GE Healthcare), lysates
were adjusted to a final concentration of 500 mM NaCl and 40 mM Imidazole pH 7.4. Pro-
tein was loaded onto the column by ON recirculation at a flowrate of 1 ml per minute at 4 ° C
using a peristaltic pump. The loaded column was transferred to the pre-equilibrated FPLC
system, washed with binding buffer and fusion protein was eluted with 250 mM imidazole
in 1 x PBS containing 500 mM NaCl (elution buffer). To eliminate imidazole, eluates were
pooled and dialysed twice ON against 1 x PBS containing 10 % Glycerol. Protein con-
centration was determined using the Bio-RAD DC assay according to the manufacturer’s
instructions and sterile filtered purified proteins were stored at -20 ° C.
3.2.11 Enrichment of specific IgGs from IVIG
For enrichment of S. aureus specific IgGs, 5 to 10 mg of purified recombinant protein (BT1,
BT2 or BT3) was covalently linked to N-hydroxysuccinimide-activated Sepharose (NHS;
HiTrapTM NHS activated HP columns) columns according to manufacturer’s instructions (GE
Healthcare). Binding of IgGs was performed ON at 4 ° C by slow recirculation of IVIG-DS .
Specifically bound IgGs were eluted from the column by pH shifting using 0.1 M glycine-HCl
(pH 2.7) with the ÄKTApurifier liquid chromatography system. The pH of the eluted fractions
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was neutralised by addition of a sufficient amount of 1 M Tris-HCl (pH 9.0). IgG-containing
fractions were pooled and, after buffer exchange into PBS (pH 7.3) using the HiPrepTM
26/10 desalting column, concentrated using Centricon Plus-70 kDa cut off centrifugal filter
units (Millipore) stored sterile filtered at 4 ° C .
3.2.12 Surface localisation of vaccine candidates
To assess the surface localisation of the antigens, S. aureus strain ATCC 29213 GFP was
inoculated into LB broth and grown at 37 ° C to an OD600 of 0.3. Bacteria were harvested,
washed and adjusted to 1 x 108 CFU/ml in PBS containing 5 % bovine serum albumin
(BSA) and 1 % normal mouse serum (MS) to block non-specific binding to Protein A. IVIG,
dSaIVIG, or enriched specific IgGs (anti-BT1, anti-BT2, and anti-BT3) were added in a con-
centration of 5 µg/ml as primary antibodies, incubated for 30 minutes at RT and washed with
PBS-0.5 % BSA to remove free antibodies. A 1:100 dilution of a phycoerythrin-conjugated
goat anti-human FcγF(ab)2 fragment (Dianova) was used as secondary antibody and was
incubated for 30 minutes at RT in the dark. After removal of free secondary antibodies,
samples were diluted 1:5 in PBS-0.5 % BSA and analysed by flow cytometry using the
FACSCalibur system and CELLQuestPro software (BD Biosciences).
3.2.13 In vitro opsonophagocytosis of S. aureus by human neutrophils
Human polymorphonuclear cells (PMNs) were isolated by dextran sedimentation and Ficoll-
Hypaque gradient centrifugation from 50 ml of heparinised blood from a healthy donor ac-
cording to standard protocols. Isolated human PMNs were resuspended in HBSS pH 7.3,
and number of cells was determined by trypan blue exclusion in a Neubauer chamber. For
the opsonophagocytosis assay S. aureus ATCC 29213-GFP was inoculated into LB broth
and grown at 37 ° C to an OD 600 of 0.3. Bacteria were harvested, washed and adjusted
to 1 x 109 CFU/ml. IVIG, dSaIVIG and specific human IgGs (anti-BT1, anti-BT2, and anti-
BT3), enriched from IVIG, were added at a concentration of 100 µg/ml and pre-opsonisation
of bacteria was allowed for 20 minutes at 37 ° C. Bacterial uptake in the presence of 2.5 %
human serum or HI-serum was used as control. 2.5 x 106 human PMNs and bacteria at a
multiplicity of infection (MOI) of 10 were incubated for 5 minutes at 37 ° C with slow rotation
upon initial synchronisation of infection by centrifugation at 400 g for 2 minutes. Phagocyto-
sis was stopped by centrifugation for 5 minutes at 150 g at 4 ° C, and samples were washed
three times, resuspended in HBSS and samples were taken for FACS analysis (1:5 dilution
in PBS-0.5 % BSA (pH 7.3); kept on ice until measurement) using the FACSCalibur and
Cellquest Pro Software.
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3.2.14 In vitro opsonophagocytic killing of S. aureus by human neutrophils
To assess killing of S. aureus by neutophils, in contrast to samples intended for analysis of
phagocytosis extracellular bacteria were not removed by differential centrifugation. PMNs
and samples were isolated and adjusted as described in 3.2.13. Immediately after addition
of bacteria (t0) 50 µl of each sample was taken to assess the initial CFU number and subse-
quently samples were centrifuged at 400 g for 2 minutes at 25 ° C, to synchronise infection,
followed by incubation in the rotating wheel at 37 ° C for 10 minutes (t12). At indicated time
points upon incubation at 37 ° C in the rotating wheel (t12, t22, t32 and t92) 50 µl of each
sample was taken and diluted 1:50 in PMN lysis buffer(5 mM Na2CO3 pH 11), to enable
PMN lysis during incubation for 10 minutes at RT. Subsequently samples were further di-
luted 1:10 in PMN lysis buffer and plated on Mueller-Hinton agar using the spiral plater.
Upon incubation at 37 ° C for 16 hours CFU were enumerated using the Countermat Flash
(IUL Instruments) and percent killing was calculated by dividing the number of CFUs at the
given time point (t12, t22, t32 and t92) by the initial CFU number (t0) of the respective sam-
ple multiplied by 100. S. aureus incubated without PMNs were included to assess bacterial
growth under experimental conditions. Experiments were performed using triplicates.
3.2.15 Immunisation of mice
Female BALB/c mice (6 to 8 weeks old) were purchased from Charles River Laboratories.
Mice were injected intraperitoneally with a 1:1 emulsion (total volume, 200 µl) containing
80 µg recombinant protein (BT1, BT2, or BT3) and complete Freund’s adjuvant (Sigma)
on day 0, followed by subcutaneous administration of two booster doses using an emul-
sion containing 40 µg antigen and incomplete Freund’s adjuvant (1:1) on days 31 and 59.
Mice immunised with BSA as non-specific antigen served as controls. For the bivalent
immunisation using recombinant BT1 and BT3 50 or 25 µg of each antigen was used for
initial or booster immunisation, respectively, to not exceed the total amount of 40 or 20 µg
used for single target immunisation. To determine the specific antibody titre, blood samples
were taken on days 14, 45, 66 by retro-orbital bleeding under anaesthesia and analysed by
ELISA on respective 0.5 µg/ml antigen and total E. coli lysate as control antigen in a 5-fold
serial dilution using the OptiEIATM TMB substrate reagent set (BD Biosciences) according
to the manufacturer’s instructions. The titre is given as the dilution corresponding to the half
maximal antibody response.
3.2.16 Murine model of sepsis
One week after the last booster immunisation BALB/c mice (n = 11 to 12) were challenged
with LD 50 of S. aureus ATCC 29213 by intravenous (i.v.) injection of 3 x 107 CFU in 300 µl
PBS. Mice were monitored daily for clinical signs of infection and mortality for 14 days.
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3.2.17 Statistical analysis
Growth curve results were statistically analysed by one-way ANOVA, followed by Bonfer-
roni post analysis using GraphPad Prism version 5.03 for Windows (GraphPad Software,
www.graphpad.com). Microarray data were analysed by unpaired, two-tailed student’s t-test
including Benjamini-Hochberg correction to minimise the false discovery rate (Benjamini
and Hochberg, 1995) using Acuity (Molecular Devices). Survival curves (Kaplan-Meier)
were analysed by the Gehan-Breslow-Wilcoxon test implemented in Graphpad Prism 5.
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4.1 Characterisation of the bacteriostatic effect mediated by S. aureus
specific IgGs
4.1.1 Human serum inhibits in vitro growth of S. aureus
It was observed previously that human serum exhibits a bacteriostatic effect on growth of
S. aureus and that this bacteriostatic effect most likely is caused by antibodies (Ehrenkranz
et al., 1971). Since this effect would be highly beneficial regarding the use of antibod-
ies in passive immunisation, we aimed to confirm this finding. To this end S. aureus was
co-cultured with 25 or 50 % of complete or heat-inactivated (HI) human serum in vitro, to
measure the potential bacteriostatic effect in a classical colony forming unit (CFU) enu-
meration assay. As shown in Figure 4.1, growth of S. aureus was statistically significantly
inhibited in the presence of either 25 % (A) or 50 % (B) human serum compared to control
samples, cultured in the presence of an equal amount of PBS or solely LB. Moreover, no
difference in the inhibitory capacity of heat-inactivated human serum (HI-serum) compared
to complete human serum was detected, hence indicating that heat-stable components,
most presumably IgGs, in the serum cause the bacteriostatic effect.
4.1.2 Intravenous immunoglobulin preparation (IVIG) specifically inhibits in vitro
growth of S. aureus
To determine whether bacteriostasis is mediated by S. aureus specific IgGs, an IVIG prepa-
ration, previously shown to contain opsonising IgGs specific for S. aureus (Glowalla et al.,
2009), was tested for effects on bacterial growth. For this purpose S. aureus was incubated
in the presence of either 25 or 50 % IVIG and samples where 25 or 50 % of the culture
volume was replaced by PBS served as control.
As shown in Figure 4.2, growth of S. aureus was statistically significantly inhibited for
up to 120 minutes upon addition of IVIG. Although the number of CFUs in IVIG-treated
samples slightly increased after 120 minutes, the number of CFUs was significantly lower
in comparison to the respective PBS control 180 minutes after addition of IgGs.
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Figure 4.1:
Effect of human serum on in vitro growth of S. aureus. Growth kinetics of S. aureus in LB
(open circles) and upon addition of 25 % (A) or 50 % (B) of human serum (red closed triangles),
heat-inactivated human serum (HI-serum; closed triangles) or an equal amount of PBS (open
triangles), respectively was assessed using a CFU enumeration assay. At indicated time points
50 µl diluted bacterial culture was spirally plated on Mueller-Hinton agar, incubated for up to 16 h
at 37 ° C and subsequently CFU per ml were counted. Shown are mean and SD of triplicates
from a representative experiment. Statistical significance between serum treated compared to
the respective PBS control sample was determined by one-way ANOVA followed by Bonferroni
post analysis. P-values are indicated by asterisks (∗ ∗ ∗ = p< 0.001).
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Figure 4.2:
Effect of IVIG on in vitro growth of S. aureus. Growth kinetics of S. aureus in LB (open circles)
and upon addition of 25 % (A) or 50 % (B) IVIG (closed triangles) or an equal amount of PBS
(open triangles), respectively was assessed using a CFU enumeration assay as described above.
Shown are mean and SD of triplicates from a representative experiment. Statistical significance
between IVIG treated compared to respective PBS control sample was determined by one-way
ANOVA followed by Bonferroni post analysis. P-values are indicated by asterisks (∗ = p< 0.05;
∗∗ = p< 0.01; ∗ ∗ ∗ = p< 0.001).
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4.1.3 Bacteriostatic effect on S. aureus is mediated by S. aureus specific IgGs
To ensure that the observed inhibitory effect mediated by IVIG is not due to changes in cul-
turing conditions by the addition of protein, the experiments were performed using 13 mg / ml
BSA or IVIG adjusted in PBS, respectively. This concentration of IVIG equates to 25 %
IVIG as used in previously described experiments. In contrast to IVIG treatment the co-
incubation of S. aureus with BSA led to significant but only minor inhibition of growth (Fig.
4.3 A), thereby indicating that bacteriostasis is a specific effect mediated by IVIG.
control LB BSA IVIG
0
25
50
75
100
125
***
***
*
120 min
C
F
U
 / 
m
l
(%
 o
f 
co
nt
ro
l)
control LB IVIG-DS IVIG
0
25
50
75
100
125
***
***
120 min
C
F
U
 / 
m
l
(%
 o
f 
co
nt
ro
l)
A
B
Figure 4.3:
Effect of BSA or IVIG-DS on in vitro growth of S. aureus. Growth kinetics of S. aureus in LB
and upon addition of 13 mg / ml BSA (A) or dialysed IVIG (IVIG-DS; B) compared to IVIG in PBS
was assessed using a CFU enumeration assay. Samples supplemented with 50 % PBS served as
control. Shown are mean and SD of triplicates in percent of PBS control 120 minutes after addition
of the respective substances. Statistical significance between indicated samples (capped lines)
was determined by one-way ANOVA followed by Bonferroni post analysis. P-values are indicated
by asterisks (∗ ∗ ∗ = p< 0.001).
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Figure 4.4:
Effect of IVIG on in vitro growth of S. aureus upon depletion of S. aureus or E. coli specific
IgGs. Growth kinetics of S. aureus in LB and upon addition of 13 mg / ml IVIG or IVIG upon
depletion of S. aureus specific IgGs (dSaIVIG) was assessed using a CFU enumeration assay.
Samples supplemented with 50 % PBS, 50 % PBS co-incubated with S. aureus (dSaPBS) or
13 mg / ml IVIG depleted of E. coli specific IgGs (dEcIVIG) served as control. Shown are mean
and SD of triplicates in percent of the given PBS control 120 minutes after addition of the re-
spective substances. Statistical significance between indicated samples (capped lines) was de-
termined by one-way ANOVA followed by Bonferroni post analysis. P-values are indicated by
asterisks (∗ ∗ ∗ = p< 0.001).
Furthermore, when IVIG dialysed against PBS (IVIG-DS) was used, the bacteriostatic
effect remained (Fig. 4.3 B), indicating that the observed bacteriostatic effect is solely due
to the presence of IgGs and independent of the buffer composition of the original IVIG
preparation. To elucidate whether S. aureus specific antibodies are responsible for the
bacteriostatic effect, IVIG was depleted of S. aureus specific IgGs (dSaIVIG) ON at 4 ° C
and upon sterile filtration used as source of non-specific IgGs in a CFU enumeration assay.
To rule out possible side effects caused by the process of depletion, PBS after ON co-
incubation with S. aureus (dSaPBS) and IVIG depleted of E. coli specific IgGs (dEcIVIG)
were used as additional controls.
When S. aureus was cultured in the presence of dSaIVIG, growth was comparable to
bacteria cultured without IgGs (PBS control, LB; Fig. 4.4). In contrast, growth of S. aureus
cultured in the presence of dEcIVIG was inhibited to a comparable extent as bacteria cul-
tured in the presence of IVIG. Hence, these results imply that S. aureus specific IgGs are
responsible for the bacteriostatic effect on growth of S. aureus.
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4.1.4 Gene expression profiling of S. aureus over the course of bacteriostasis
To elucidate the mechanism leading to the observed bacteriostatic effect elicited by specific
IgGs on S. aureus growth, gene expression profiling was performed. For this purpose the
culturing conditions were optimised to the minimal IVIG concentration, sufficient to elicit
bacteriostasis and an elevated initial number of S. aureus-CFUs (1 x 107 / ml instead of
1 x 104 / ml), in order to enable isolation of an adequate amount of RNA for subsequent
microarray analyses. Due to these changes in the experimental setup, the duration of the
bacteriostatic effect slightly decreased (see Fig. 4.5).
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Figure 4.5:
Growth kinetics of S. aureus for RNA isolation. A growth curve of S. aureus cultured in the
presence of 50 % PBS (black open triangles) 2.5 mg / ml IVIG (red open triangles) or dSaIVIG
(green open triangles) was assessed by CFU enumeration assay. Shown are mean and SD of
triplicates from a representative experiment. Arrows indicate time point of RNA isolation and filled
triangles in the respective colour represent CFU / ml in RNA sample immediately prior to RNA
isolation. Statistical significance of the difference of IVIG compared to dSaIVIG treated samples
was determined by one-way ANOVA followed by Bonferroni post analysis. P-values are indicated
by asterisks (∗ = p< 0.05; ∗∗ = p< 0.01).
The RNA of IVIG, dSaIVIG and PBS supplemented S. aureus cultures was isolated im-
mediately upon addition of IgGs or PBS (t0), during inhibition (t30) and shortly before IVIG
treated cultures start to grow (t60). For subsequent hybridisation to the S. aureus specific
microarray samples were indirectly labelled with Cy5- (IVIG) and Cy3-dyes (dSaIVIG or
PBS). The employed microarray comprises all predicted open reading frames present in
any of seven fully sequenced S. aureus - genomes (Witney et al., 2005), thereby account-
ing for the high variability in staphylococcal genomes.
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Figure 4.6:
Differentially expressed genes in IVIG compared to dSaIVIG samples distributed into func-
tional categories. Differentially expressed genes within IVIG treated samples compared to
dSaIVIG samples over the whole time course were distributed into functional categories accord-
ing to gene annotation. All genes showed at least 1.5-fold up- (A) or downregulation (B) in at least
three of four arrays with p< 0.05 after Benjamini-Hochberg correction at any of the analysed time
points (t0, t30 and t60). Numbers in parentheses indicate number of genes related to iron uptake.
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Table 4.1:
Differentially expressed genes related to iron uptake and metabolism in IVIG versus dSaIVIG
treated samples revealed by microarray analysis
Common a) Predicted function GI protein
t0 t30 t60
FC b) p-value c) FC b) p-value c) FC b) p-value c)
Regulation of iron uptake and storage:
fur iron uptake regulatory protein 49483748 -1.5 0.019
Iron storage and prevention of oxidative stress:
SAR1344 catalase 49483526 -2.8 0.019 -2.0 0.017
SAR1984 ferritin 49484134 -2.6 0.035 -4.7 0.019 -4.1 0.017
SAR2227 non-heme iron-containing ferritin 49484363 -2.9 0.017
Porphyrin synthesis:
hemC porphobilinogen deaminase 49483913 -1.6 0.014
hemD uroporphyrinogen III synthase 49483912 -1.5 0.012
Siderophore mediated iron uptake:
fhuB ferrichrome transport permease 49482876 2.1 0.026
fhuC ferrichrome transport ATP-binding protein 49482875 2.4 0.026 1.9 0.016
fhuD ferrichrome transport permease 49482877 2.1 0.036 1.8 0.017
fhuD2 ferrichrome-binding lipoprotein precursor 49484499 2.4 0.039
sirA lipoprotein 49482358 7.9 0.019 4.4 0.018
sirB siderophore transport system permease 49482357 5.8 0.019 3.4 0.017
sirC siderophore transport system permease 49482356 3.5 0.038
sstA FecCD transport family protein 49482990 3.8 0.034
sstB FecCD transport family protein 49482991 5.6 0.032 4.1 0.028
sstC ABC transporter ATP-binding protein 49482992 2.3 0.025 7.8 0.019 4.7 0.017
sstD lipoprotein 49482993 9.3 0.019 4.6 0.017
SAR2266 FecCD transport family protein 49484395 3.4 0.030 2.3 0.023
SAR2268 transport system binding lipoprotein 49484397 6.0 0.019 3.9 0.019
Associated with siderophore uptake:
sbnA pyridoxal-phosphate dependent enzyme 49482359 3.5 0.033
sbnB put. ornithine cyclodeaminase 49482360 4.7 0.017
sbnC put. siderophore biosynthesis protein 49482361 3.9 0.012
sbnD put. transport protein 49482362 3.0 0.012
sbnE put. siderophore biosynthesis protein 49482363 3.1 0.017
sbnF put. siderophore biosynthesis protein 49482364 2.6 0.017
sbnG put. aldolase 49482365 2.8 0.012
sbnH pyridoxal-dependent decarboxylase 49482366 2.1 0.012
sbnI hypothetical protein 49482367 2.3 0.012
ribA riboflavin biosynthesis protein 49484013 4.8 0.024 21.2 0.006 8.8 0.013
ribD bifunctional riboflavin biosynthesis protein 49484015 5.1 0.017 16.9 0.006 7.9 0.012
ribE riboflavin synthase alpha chain 49484014 4.7 0.049 15.2 0.019 8.3 0.013
ribH 6,7-dimethyl-8-ribityllumazine synthase 49484012 3.8 0.036 13.0 0.006 6.6 0.013
Uptake of heme or transferrin bound iron:
isdI heme-degrading monooxygenase 49482408 1.7 0.049 2.4 0.043 2.4 0.038
isdA iron-regulated heme-iron binding protein 49483292 3.0 0.030 1.7 0.026
isdC put. surface anchored protein 49483293 2.7 0.019 2.8 0.020
srtB sortase B 49483297 5.3 0.037 3.4 0.012
a) Prefix SAR, MRSA252 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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To identify differentially expressed genes in IVIG treated samples at each time point (t0,
t30 and t60), microarrays were hybridised in parallel with either IVIG and dSaIVIG (source
of non-specific IgGs) treated samples (microarray set A), or IVIG and PBS treated samples
(microarray set B) for each time point. Only genes showing a minimum fold change of
1.5 in at least three of the four arrays for each time point (biological replicates) with a p-
value of less than 0.05 upon Benjamini-Hochberg correction were taken into account. The
microarray analysis of IVIG compared to dSaIVIG (microarray set A) or PBS (microarray set
B) led to the identification of divergent sets of differentially expressed candidate genes.
Concerning the dSaIVIG control (microarray set A), Figure 4.6 illustrates the distribution
of all genes matching these criteria into functional categories upon co-hybridisation of IVIG
with dSaIVIG at any of the analysed time points. In total 236 genes were found to be dif-
ferentially expressed in IVIG compared to dSaIVIG samples. As shown in figure 4.6 A, 120
genes were upregulated and the remaining 116 genes were downregulated (Fig. 4.6 B)
Since S. aureus genomes contain many ORFs coding for so far uncharacterised proteins, it
is not surprising that the largest group, with in total 89 genes, represents genes with yet un-
known function. Interestingly 19 genes of the in total 28 genes in the second largest group
representing genes linked to inorganic compound transport and metabolism are related to
iron uptake. In addition, further 17 genes related to iron uptake or metabolism were found
in other functional categories (numbers given in parentheses). While the majority of these
genes were upregulated, only six genes were downregulated in IVIG treated samples. The
ferric uptake regulator fur was 1.5-fold downregulated at t30 and the expression of its target
genes was altered accordingly (Dale et al., 2004b; Horsburgh et al., 2001b; Speziali et al.,
2006). Dependent on the predicted function in iron uptake these genes were arranged and
the fold change as well as the respective p-value for each time point are listed in Table 4.1
(for all 236 genes see Table 9.2 in supplement, page 78 ff.).
The in parallel performed microarray analysis of IVIG samples co-hybridised with PBS
samples as additional control (microarray set B) resulted in 78 genes matching the filter-
ing criteria for the identification of differentially expressed genes. Only 13 of these genes
were also identified as differentially expressed in the other set of microarray analysis (IVIG
versus dSaIVIG; Table 9.1, page 78). Surprisingly, none of these genes is related to iron up-
take or metabolism, hence indicating a strong difference between the two applied controls
(dSaIVIG and PBS). Furthermore, there was no apparent functional connection between
these candidates.
A distribution of all up- or downregulated genes among the 78 candidate genes according
to functional categories is depicted in Figure 4.7 A and B, respectively. Again almost one
third of the identified genes belong to the group of unknown function. Followed by the
two groups of genes related to aminoacid- (in total 11 genes) and carbohydrate transport
and metabolism (in total 9 genes). Two or four additional genes related to aminoacid or
carbohydrate metabolism, respectively were identified in other functional groups.
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Figure 4.7:
Differentially expressed genes in IVIG compared to PBS samples distributed into func-
tional categories. Differentially expressed genes within IVIG treated samples compared to PBS
samples over the whole time course were distributed into functional categories according to gene
annotation. All genes showed at least 1.5-fold up- (A) or downregulation (B) in at least three of
four arrays with p< 0.05 after Benjamini-Hochberg correction at any of the analysed time points
(t0, t30 and t60).
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All genes falling into one of these two categories, including potential regulators are listed
in Table 4.2 (for all 78 genes see Table 9.3 in supplement, page 84 ff.). Since most of the
candidates related to carbohydrate transport and metabolism were not identified as differ-
entially expressed during inhibition (t30), these are rather unlikely involved in bacteriostasis.
Table 4.2:
Main clusters of differentially expressed genes in IVIG related to PBS treated samples revealed
by microarray analysis
Common a) Predicted function GI protein
t0 t30 t60
FC b) p-value c) FC b) p-value c) FC b) p-value c)
Aminoacid transport and metabolism:
lysP lysine-specific permease 49483924 -1.6 0.015
oppB oligopeptide transport system permease 49483147 -2.1 0.020
oppC oligopeptide transport system permease 49483148 -1.8 0.033 -2.1 0.017
pyrAA put. carbamoyl-phosphate synthase, 49483365 -1.9 0.043
pyrimidine-specific, small chain
rocD ornithine aminotransferase 49483117 -1.7 0.017
SAR0243 put. zinc-binding dehydrogenase 49482482 -1.8 0.037
SAR0521 GntR family regulatory protein 49482747 -1.8 0.033 -1.8 0.015 -1.8 0.037
SAR0920 NAD-specific glutamate dehydrogenase 49483118 4.0 0.043
SAR1338 put. homoserine dehydrogenase 49483520 -4.6 0.031
SAR1702 put. cysteine desulfurase 49483867 -1.6 0.033
SAR1703 put. oxygenase 49483868 -1.7 0.037
SAR1849 proline dehydrogenase 49484011 -2.6 0.021
SAR2682 put. aminotransferase 49484800 -2.5 0.017
Carbohydrate transport and metabolism:
bglA 6-phospho-beta-glucosidase SAR0264 49482503 3.9 0.043
fdaB fructose 1,6 bisphosphate aldolase 88196553 2.2 0.037
fruA PTS transport system, fructose-specific 49482956 1.8 0.043
IIABC component
glpD aerobic glycerol-3-phosphate dehydrogenase 49483464 3.0 0.037
glpF put. glycerol uptake facilitator protein 49483462 5.3 0.043
SAR0205 put. maltose ABC transporter, 49482446 -2.4 0.016
ATP-binding protein
SAR0660 DhaK subunit 49482878
SAR2399 put. transcription regulator 49484531 -1.7 0.037
SAR2408 PTS system, arbutin-like IIBC component 49484538 -2.8 0.017
SAR2409 put. transcription regulator 49484539 -1.8 0.045
SAR2589 put. glucarate transporter 49484713 6.4 0.037
scrR sucrose operon repressor 49484268 2.1 0.043
uhpT put. sugar phosphate transport protein 49482454 -2.6 0.029
a) Prefix SAR, MRSA252 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
Due to the pivotal role of iron for growth of bacteria, the prominent signature of iron related
genes as detected by microarray set A, could explain the observed bacteriostatic effect in
IVIG treated samples. Especially, as a direct bacteriostatic effect of immunogobulins by
interference with iron uptake was already shown for other bacterial species (Fitzgerald and
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Rogers, 1980; Goel and Kapil, 2001). Thus, quantitative real time PCR (qPCR) for selected
iron related genes was applied to validate the microarray results and to analyse, whether
the iron signature was just missed by IVIG vs. PBS arrays, due to the stringent filtering
criteria.
As shown in Figure 4.8, qPCR results for each analysed gene (fur, catalase, fhuC, fhuD2,
ferritin and ribA) show a similar fold change of gene expression as was measured by mi-
croarray analysis, hence verifying microarray data. Since qPCR is more sensitive than
microarray analyses it is not surprising that in contrast to microarray results three of the
tested genes (fur, fhuC and fhuD2) are already more than 1.5-fold up- or downregulated at
t0 or t0 and t60 in case of fhuD2 expression.
Furthermore, qPCR analysis (Fig. 4.9) confirmed that the iron signature as identified by
comparison of IVIG to dSaIVIG samples (black bars) is not detectable by analysis of IVIG
versus PBS samples (grey bars). Whereas in case of qPCR for fur or catalase at t0 or
t0 and t30, respectively the IVIG vs. PBS samples only marginally failed the fold change
filter (1.5- fold), the qPCR results for all other tested genes clearly demonstrated that the
iron signature as identified by microarray set A is not present in comparison of IVIG to PBS
treated samples (microarray set B). Moreover, qPCR results of dSaIVIG related to PBS
treated samples (white bars) revealed that the iron signature is most likely derived from
dSaIVIG, since the obtained results represent the almost exact reciprocal values of IVIG
related to dSaIVIG (black bars). Hence the iron signature is not representing the mecha-
nism underlying bacteriostasis and, most importantly, the data obtained with dSaIVIG are
not applicable for further investigation of this mechanism. Since the depletion of S. aureus
specific IgGs was performed by ON incubation with viable staphylococci at 4 ° C, it is likely
that next to high affinity iron chelators (siderophores) also other staphylococcal factors af-
fecting microarray analyses are secreted and not eliminated by filtration. For example the
most likely pre-existing siderophores in dSaIVIG apparently lead to an immediate supply of
S. aureus with iron at early time points, thus causing the false identification of the iron signa-
ture by microarray set A. To overcome this problem in future, a chromatographic purification
of IgGs subsequent to depletion of specific IgGs is essential.
Prerequisite for the identification of genes involved in the mechanism underlying the ob-
served bacteriostatic effect mediated by S. aureus specific IgGs is a reliable gene expres-
sion signature. Consequently, since under the used conditions no distinct signature could
be identified, any further characterisation was infeasible. Therefore, the bacteriostatic ef-
fect on S. aureus can currently not serve as a selection criterion for the search of protective
antibodies. Thus, our further search for protective S. aureus specific antibodies was based
on a subtractive selection procedure recently developed in our laboratory.
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Figure 4.8:
Comparison of qPCR results to microarray results. RNA of IVIG and dSaIVIG samples for
each time point (t0, t30 and t60) was reverse transcribed into cDNA in triplicate. The qPCR was
performed using primers specific for fur (A), catalase (B), fhuC (C), fhuD2 (D), ferritin (E) and
ribA (F). Shown is the fold change in expression of the respective gene in IVIG versus dSaIVIG
samples (white bars) compared to the respective microarray result (black bars) for each time point.
Represented is mean and SD. Red lines indicate a fold change of 1.5.
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Figure 4.9:
qPCR results of IVIG vs. dSaIVIG and IVIG or dSaIVIG vs PBS. RNA of IVIG, dSaIVIG and
PBS treated samples for each time point (t0, t30 and t60) was reverse transcribed into cDNA in
triplicate. The qPCR was performed using primers specific for fur (A), catalase (B), fhuC (C),
fhuD2 (D), ferritin (E) and ribA (F). Shown is the fold change in expression of the respective gene
in IVIG versus dSaIVIG samples (black bars), IVIG vs. PBS (grey bars) and dSaIVIG vs. PBS
(white bars) for each time point. Represented is mean and SD. Red lines indicate a fold change
of 1.5.
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4.2 Identification and characterisation of potential vaccine candidates
against S. aureus
4.2.1 Subtractive proteome analysis (SUPRA) of anchorless cell wall (ACW) proteins
enables identification of potential vaccine candidates against S. aureus
Anchorless cell wall proteins (ACW proteins) from S. aureus strain ATCC 29213 were sep-
arated by 2-DE, followed by Western blot analysis using IVIG and dSaIVIG to identify anti-
genic proteins. To obtain high-quality spot resolution and to ensure adequate spot matching
and identification, proteins were separated using two different pH ranges, pH 3 to 10 (Fig.
4.10) and pH 4 to 7 (not shown), in a series of three gels in parallel. One gel was used
for immunoblotting, probing the same blot twice, first with dSaIVIG (Fig. 4.10 A) and sub-
sequently with IVIG (Fig. 4.10 B). The two remaining gels were stained for spotmatching
(silver; C) and excision of protein spots (Coomassie; D). IVIG and dSaIVIG produced repro-
ducibly distinct immunoblot profiles for S. aureus ACW proteins in at least three individual
experiments. The depletion of S. aureus specific, opsonising IgGs (dSaIVIG) resulted in
a considerably lower number of protein spots compared to immunoblots probed with IVIG
(compare Fig. 4.10 A and B). Proteins recognised by complete IVIG but not dSaIVIG were
referred to as potential vaccine candidates, based on the assumption that these are de-
tected by naturally occurring S. aureus specific IgGs, hence representing in vivo expressed
antigens. In contrast, protein spots strongly reacting with both IVIG and dSaIVIG were ex-
cluded from further investigation, since these are more likely to be recognised by IgGs that
lack specificity for S. aureus antigens. Furthermore, protein spots not detected in all three
individual experiments were also excluded from subsequent analysis. Protein spots of inter-
est were excised from Coomassie stained gels and used for identification by MALDI - TOF
analysis. To account for potential variability in the IgG repertoire, a second IVIG preparation
(Venimmun ® N) was used for Western blot analysis, revealing an almost identical protein
pattern as obtained using Octagam ®. A total of 37 proteins detected by both IVIG prepa-
rations were identified using SUPRA (see Table 4.3). Except for four candidate proteins,
namely, enterotoxin M and three hypothetical proteins (spot ID 2089, 2222, and 2240), all
identified proteins are highly conserved in S. aureus, since their sequences were present
in all 15 completely sequenced genomes of S. aureus, currently available in the GenBank
database. These four proteins not conserved among sequenced S. aureus strains were
excluded from further investigation because ubiquitous occurrence is a major prerequisite
for a vaccine candidate.
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Figure 4.10:
Subtractive proteome analysis (SUPRA) of S. aureus ACW proteins using IVIG and dSaIVIG
ACW proteins isolated from S. aureus strain ATCC 29213 were separated according to their iso-
electric points on pI 3 to 10 IPG strips. Gels loaded with 100 µg protein were used for subtractive
immunoblotting. Spots not immunoreactive with dSaIVIG (A) but immunoreactive with IVIG (B)
were spots predicted to be promising vaccine candidates (circles). Spots immunoreactive with
both IVIG and dSaIVIG were excluded from further investigation. For MALDI-TOF identification
corresponding spots were matched with preparative gels loaded with 500 µg protein (C and D).
SUPRA was performed in collaboration with Eva Glowalla.
47
4 Results
Table 4.3: Immunogenic anchorless cell wall proteins from S. aureus ATCC 29213 identified by SUPRA
GI protein Spot ID Predicted function pI a)
MW MASCOT Sequence
kDa) b) Total Coverage
Score c)
1 15927930 2160 hypothetical protein, similar to esterase (hp2160) 1,2 7.2 35.6 92 28
2 15926453 2338 enolase (eno) 1,2 4.6 47.1 206 47
3 15926814 2357 3-oxoacyl- (acyl-carrier protein) reductase (oxo) 1,2 5.6 26.2 103 35
4 21204821 2228 alanine dehydrogenase 5.6 40.1 268 55
5 14247692 2053 aldehyde dehydrogenase 6.6 51.9 56 15
6 15924043 2221 autolysin 9.7 102.6 77 11
7 15926504 2077 aminotransferase NifS homologue 5.3 46.4 346 60
8 15927677 2226 ATP synthase beta chain 4.7 51.4 317 55
9 14247509 2237 chorismate mutase homolog 5.8 40.7 112 34
10 15926560 2042 conserved hypothetical protein 5.6 31.8 121 48
11 15926780 2161 conserved hypothetical protein 5.7 34.6 186 45
12 15928275 2342 conserved hypothetical protein 5.3 37.5 188 33
13 14247601 2244 enterotoxin SEM 6.5 27.5 68 28
14 15926324 2247 ferrichrome transport ATP-binding protein 5.6 29.7 99 28
15 6578924 2070 glutamyl-t-RNA-Gln amidotransferase subunit A 5.0 52.3 143 36
16 15926530 2036/2078 hypothetical protein, similar to NADH dehydrogenase 5.4 44.4 79 29
17 15926396 2037/2038 hypothetical protein, similar to anion-binding protein 9.0 74.4 248 38
18 21205078 2222 hypothetical protein 5.8 65.5 63 13
19 15927580 2425 hypothetical protein, 8.6 38.7 78 14
20 15923845 2089 hypothetical protein 5.7 29.4 113 38
21 15928230 2235 hypothetical protein, similar to autolysin precursor 6.0 69.2 72 16
22 15927670 2239 hypothetical protein, similar to SceD precursor 5.5 24.1 70 34
23 15923892 2240 hypothetical protein 6.5 37.1 89 19
24 15928148
2043/2050/2094/
immunodominant antigen A 6.1 24.2 80 23
2096/2099
25 15926547 2232 NAD-specific glutamate dehydrogenase 5.2 45.9 255 50
26 2239274 2039/2345 peptidoglycan hydrolase 6.1 35.2 63 22
27 15925843 2229/2230 phosphopentomutase 5.0 43.8 229 60
28 14247604 2406 protoporphyrinogen oxygenase 6.3 52.2 126 23
29 15927798 2158 50S ribosomal protein L13 9.3 16.3 228 66
30 15926178 2346 50S ribosomal protein L25 4.4 23.8 104 34
31 15927879 2155 secretory antigen precursor SsaA homolog 9.0 29.4 112 40
32 15926226 2084/2219/2227 translational elongation factor TU 4.7 43.1 98 33
33 15926838 2242 transcription pleiotropic repressor codY 5.9 28.7 178 49
34 15926451 2353 triosephosphate isomerase 4.8 27.4 66 32
35 21205110 2056 truncated beta-hemolysin 8.8 37.5 105 42
36 15926841 2241 uridylate kinase 6.0 26.3 88 26
37 13701328 2374 Xaa-Pro dipeptidase 5.2 39.6 241 36
a) Theoretical pI
b) Theoretical molecular weight
c) Identification probability of the peptide match
1 Short name of candidate given in parentheses
2 Characterisation described in Glowalla et al. 2009
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Furthermore, the two most obvious candidates S. aureus protein A (Spa, several spots
between 45 and 66 kDa) and immunodominant antigen A (IsaA), which was previously
reported to be highly immunogenic (Vytvytska et al., 2002) and described as an autolytic
enzyme involved in cell wall metabolism (Stapleton et al., 2007) were deferred at first from
further analysis, since they are already present at high titres in many individuals and hence
unlikely confer protection against S. aureus infection.
Three of the identified vaccine candidates, the hypothetical protein 2160 (hp2160), oxo
and eno, have already been analysed for efficacy in the prevention of S. aureus infections
upon immunisation with the respective N-terminal GST-fusion proteins in a murine model of
sepsis (Glowalla et al., 2009). Upon active immunisation also GST specific IgGs could be
detected in serum of immunised mice by ELISA and complete removal of the GST tag is
hampered by the incomplete thrombin cleavage site in pDEST15, the vector used for con-
struction of the N-terminal GST fusion proteins. Therefore, subsequent candidates were
expressed as C-terminal His-tag fusion proteins in E. coli. Expression and purification con-
ditions of BT1-His, BT2-His and BT3-His were optimised, to achieve the maximum yield of
each recombinant protein under native conditions in suitable purity.
4.2.2 BT1, BT2 and BT3 are localised on the surface of S. aureus
As surface localisation of a vaccine candidate is pivotal for opsonisation of the pathogen
by IgGs, IgGs specific for BT1, BT2 and BT3 were enriched from IVIG by affinity chro-
matography using the corresponding purified recombinant protein covalently linked to NHS-
activated columns, to enable assessment of surface localisation on viable S. aureus and in
vitro opsonophagocytic assays.
At first, as shown in Figure 4.11 A, purified IgG fractions were analysed for specificity by
western blot analysis. Each antibody fraction was able to strongly detect the corresponding
recombinant protein and, to a lesser extent, non-specific E. coli proteins. Since the major
band corresponds to the respective fusion protein the purified IgG fractions were then used
as primary antibody, to assess the surface localisation of corresponding S. aureus- antigens
by flow cytometry. As shown in Figure 4.11 B, all three antibody fractions were able to detect
more than 95 % of PE-positive viable S. aureus, therefore almost 40 % more PE-positive
gated events, than detected in samples where dSaIVIG was used as negative control. Thus,
proving surface localisation of the analysed S. aureus - antigens BT1, BT2 and BT3.
4.2.3 Affinity purified IgGs specific for BT1, BT2 and BT3 trigger
opsonophagocytosis of S. aureus by human neutrophils in vitro
Since IgGs present in IVIG represent naturally occurring antibodies, enriched IgGs for each
of the three antigens were tested regarding their potential to promote opsonophagocytosis
by human neutrophils.
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Figure 4.11:
Specificity of enriched IgGs and surface localisation of vaccine candidates A) Specificity
of affinity enriched IgGs specific for BT1 (left), BT2 (middle) and BT3 (right) was assessed by
Western Blot analysis. 10 µg of cytoplasmic protein fraction of non-transformed E. coli (first lane),
E. coli-BL21 expressing recombinant BT1, BT2 or BT3 (second lane) or 2.5 µg affinity purified
BT1, BT2 or BT3 protein (third lane) were separated by SDS PAGE. Immunoblots were probed
with affinity purified anti-BT1, anti-BT2 or anti-BT3 (1 µg/ml). Arrows indicate the respective
recombinant proteins. B) Surface localisation of BT1 (left), BT2 (middle) and BT3 (right) was
assessed by incubation of S. aureus-ATCC 29213-GFP with 5 µg/ml of either dSaIVIG (negative
control; lightgrey filled), anti-BT1, anti-BT2 or anti-BT3 for 30 min at RT. After washing, bound
IgGs were detected by PE conjugated anti-human FCγ F(ab)2 fragments and subsequently anal-
ysed by flow cytometry. S. aureus-ATCC 29213-GFP incubated with secondary antibody only is
represented by the dark-grey histogram. Given percentages represent percent of gated events in
marked region for each corresponding primary antibody (black line).
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Figure 4.12:
Opsonophagocytosis of S. aureus ATCC 29213-GFP by human neutrophils Human neu-
trophils, bacteria (MOI 10), and 2.5 % human serum, 2.5 % HI-serum or 100 µg/ml IgGs were
incubated for 5 min at 37 ° C for opsonophagocytosis, followed by differential centrifugation. Hu-
man PMNs (lightgrey filled) and bacteria with dSaIVIG (blue line) as opsonin served as negative
controls. Red lines represent specific opsonins. Green fluorescence was measured by flow cy-
tometry. Given percentages of GFP-positive human PMNs (marked region) represent the fraction
of cells with internalised ATCC 29213-GFP.
As shown in Figure 4.12 human serum, HI-serum and IVIG efficiently triggered op-
sonophagocytosis, resulting in more than 75 % GFP positive PMNs. Whereas the fraction
of GFP positive neutrophils was remarkably lower using IgGs specific for BT1 (47.4 %) and
BT2 (36.8 %), IgGs specific for BT3 triggered opsonophagocytosis in an extent comparable
to human serum, HI serum and IVIG (75.6 %). Since dSaIVIG used as negative control
equates to PMNs in the absence of S. aureus, IgGs directed against BT1 and BT2 clearly
promote phagocytosis.
4.2.4 Affinity purified IgGs specific for BT1 and BT2 mediate killing of S. aureus by
human neutrophils in vitro
Since enriched IgGs specific for each of the three candidates triggered efficient phagocy-
tosis by human neutrophils, they were then tested for their capacity to mediate subsequent
elimination of staphylococci.
As shown in Figure 4.13 S. aureus pre-opsonised with IVIG are efficiently eliminated
by human neutrophils already 12 minutes upon addition of cells, resulting in only 65 %
surviving bacteria, further decreasing to 50 % at t92. Although with a lower effect at early
time points, anti-BT1 antibodies mediated a statistically significant killing of staphylococci
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Figure 4.13:
Opsonophagocytic killing of S. aureus ATCC 29213-GFP by human neutrophils Human neu-
trophils, bacteria (MOI 10) without antibodies (black open squares) or pre-opsonised with either
2.5 % HI-serum (black closed squares) or 100 µg/ml IVIG (red closed circles), dSaIVIG (blue
closed circles), anti-BT1 (red open diamonds), anti-BT2 (green open diamonds) or anti-BT3 (blue
open diamonds) were incubated for 10 min at 37 ° C, to enable phagocytosis subsequent to syn-
chronisation of infection by a 2 minute centrifugation at 400 g in a pre-warmed centrifuge. To
assess elimination of bacteria, samples were removed immediately upon addition of bacteria (t0),
upon phagocytosis (t12) and at t22, t32 and t92. Upon lysis of PMNs, samples were spread in
a 1:500 dilution on Mueller Hinton agar plates. Shown are mean and SD of triplicates in percent
of the respective t0. Statistical significance in comparison to the sample without antibodies was
determined by one-way ANOVA followed by Bonferroni post analysis. P-values are indicated by
asterisks (∗ = p< 0.05; ∗∗ = p< 0.01; ∗ ∗ ∗ = p< 0.001).
comparable to IVIG, also resulting in only 50 % surviving bacteria at t92. The killing effect
promoted by anti-BT2 antibodies, though lower than that observed using IVIG or anti-BT1,
led to a statistically significant reduction of viable bacteria to 64 % at t92. In contrast, anti-
BT3 antibodies failed to mediate statistical significant killing of bacteria, but results obtained
for the early time points demonstrate a killing effect comparable to samples with anti-BT2
as opsonin.
4.2.5 Immunisation with recombinant BT1 and BT3 protects mice from death upon
lethal challenge with S. aureus
So far no in vitro test has the potential to predict, whether a vaccine candidate confers
protection or not. Therefore, the purified recombinant proteins BT1, BT2 and BT3 were used
for in vivo studies in BALB/c mice, to ascertain whether immunisation leads to protection
against lethal challenge with S. aureus. Immunisation resulted in a high serum titre of IgGs
for BT1 (1,199,050) and BT3 (653,048), but only 94,669 for BT2 one week after the second
booster dose, prior to infection. To assess the protective potential immunised mice were
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challenged intravenously with 3 x 107 CFU of S. aureus strain ATCC 29213 one week after
the second booster immunisation. For two weeks infected mice were monitored daily for
clinical signs of infection and mortality. Mice immunised with BSA as non-specific antigen
served as control.
As shown in Figure 4.14, 60 % of the mice immunised with either BT1 (A) or BT3 (C)
survived, in contrast to only 25 % surviving mice in the group of BSA-immunised mice. In
case of immunisation with recombinant BT2 (B) no improved survival compared to infected
control mice was observed.
To ascertain, whether immunisation with both candidates could potentiate the observed
protective effect, mice were immunised with a mixture of equal amounts of each antigen,
resulting in a serum titre comparable to single immunisation or BSA as control. As shown in
Figure 4.15, more than 65 % of the mice immunised with BT1 alone (A) survived the chal-
lenge with S. aureus in contrast to only 10 % in the BSA control group. In mice immunised
with BT3 (B) still 30 % more animals survived the challenge compared to BSA immunised
mice. In case of immunisation with a mix of recombinant BT1 and BT3 (C) the survival
rate further declined to 30 %, thus just 20 % higher than observed for mock immunised
mice. The discrepancy between single target immunisation and the bivalent immunisation
could be due to the lower amount of antigen used for immunisation, since only half of the
amount of each antigen was used for immunisation. Thus, the conditions for polyvalent
immunisations have to be further improved.
Altogether, three of the so far characterised proteins, namely hp2160, BT1 and BT3,
conferred protection in a murine model of sepsis. The remaining candidates will now be
tested consecutively, to enable the formulation of a multivalent mix of vaccine candidates
for active immunisation in order to improve the protective effects observed upon monovalent
immunisation.
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Figure 4.14:
Survival of mice challenged with LD 50 of ATCC 29213 upon monovalent immunisation
BALB/c mice immunised with recombinant BT1 (A; red line), BT2 (B; red line) and BT3 (C; red
line) or BSA as control (black line) were challenged i.v. with 3 x 107 CFU of S. aureus ATCC 29213
(n = 11 to 12). Survival was monitored for 14 days. Given are exact p-values determined by
Gehan-Breslow test
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Figure 4.15:
Survival of mice challenged with LD 50 of ATCC 29213 upon bivalent immunisation
BALB/c mice immunised with recombinant BT1 (A; red line), BT3 (B; red line) and a mix of BT1
and BT3 (C; red line) or BSA as control (black line) were challenged i.v. with 3 x 107 CFU of
S. aureus ATCC 29213 (n = 10). Survival was monitored for 14 days. Given are exact p-values
determined by Gehan-Breslow test
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S. aureus causes apart from minor skin infections severe life-threatening invasive diseases
like pneumonia, endocarditis and sepsis in healthy and especially in immunocompromised
patients. The rapid emergence of S. aureus strains resistant to Methicillin (MRSA) and
many other available antibiotics further aggravates the situation, reflected by the drastic
increase in both nosocomially and community acquired MRSA related infections and the
therewith increased mortality rates (Corriere and Decker, 2008). Thus, highlighting the
pressing need for alternative strategies to prevent and treat S. aureus infections.
5.1 Characterisation of the bacteriostatic effect mediated by S. aureus
specific IgGs
As passive immunisation is appropriate for short term usage, an antibody-based therapy is
highly desirable for the prevention and treatment of S. aureus infections. The major risk fac-
tor for S. aureus infection is for example a post-surgical infection by either an endogenous
or nosocomial S. aureus strain (Perl et al., 2002; Kluytmans et al., 1997; Wertheim et al.,
2005). But, since only few surgeries are scheduled well in advance, a strategy based on
active immunisation would most likely not be appropriate. Moreover, passive immunisation
is also applicable in immunocompromised patients, not able to trigger a sufficient humoral
response.
Furthermore, the combination of antibodies with different functionalities, e.g. neutralisa-
tion of toxins or adhesion to host cell tissue, opsonisation and subsequent phagocytosis by
professional phagocytes, would further increase the beneficial aspects of passive immuni-
sation. In this respect the observation that most likely the immunoglobulin fraction of human
serum caused bacteriostasis of S. aureus (Ehrenkranz et al., 1971), could be indicative of
a so far uncharacterised direct function mediated by S. aureus specific antibodies.
For this reason, after reproducing the results obtained with human serum, we employed
an intravenous immunoglobulin (IVIG) preparation as source of S. aureus specific IgGs in
order to analyse whether these mediate inhibition of staphylococcal growth. In fact IVIG ex-
hibited a bacteriostatic effect on S. aureus, and additional control experiments revealed that
this inhibition of growth is solely due to IgG. Moreover, IgGs responsible for bacteriostasis
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could be depleted by over night co-incubation of IVIG with S. aureus (dSaIVIG), thus proving
that S. aureus specific IgGs mediate the inhibition of growth. Since this is an indication of a
so far uncharacterised direct effect of specific IgGs against S. aureus, we aimed to analyse
the underlying mechanism. For this purpose we employed gene expression profiling, to
elucidate the response of S. aureus to the action of IgGs during bacteriostasis.
The genetic variation in S. aureus is very extensive with around 22 % of the genome
being comprised of dispensable genetic material (Fitzgerald et al., 2001), amongst others
encoding virulence factors. To account for this, we utilised the seven strain S. aureus PCR
product microarray provided by the Bacterial Microarray Group at Saint Georges (BµG@S).
This microarray is based on the genome of S. aureus strain MRSA252 and represents
all predicted ORFs present in any of the seven genomes of S. aureus strains MRSA252,
MSSA476, MW2, N315, Mu50, COL and NCTC8325.
To limit the problems connected with the several steps of microarray analysis and sam-
ple variability, each experiment for RNA isolation was performed four times. Only genes
showing a minimum fold change of 1.5 in at least three of the four arrays for each time
point (biological replicates) with a p-value of less than 0.05 upon Benjamini-Hochberg cor-
rection were taken into account. Furthermore, two different controls were applied in parallel
sets of microarray experiments; IVIG compared to dSaIVIG as source of non-specific IgGs
(microarray set A) or PBS (microarray set B).
Whereas 236 genes matched the filtering criteria for any of the analysed time points (t0,
t30 and t60) upon analysis of microarray set A, only 78 genes were found differentially ex-
pressed by comparison of IVIG to PBS (microarray set B) indicating a difference between
the two applied controls. Moreover, only 13 genes common to both sets of microarrays
were identified. Most of these 13 genes are only categorised by function prediction and
there is no obvious link between these genes and the observed bacteriostasis. In general
the major detriment of a global analysis on S. aureus gene expression analysis for the char-
acterisation of an unknown mechanism is the enormous number of so far uncharacterised
hypothetical proteins, reflected by the fact that these represent with 86 or 23 differentially
expressed genes the largest groups in microarray set A and B, respectively. Thus, almost
one third of all identified genes in both sets of arrays were not usable for further char-
acterisation of the mechanism underlying bacteriostasis. Intriguingly, the most prominent
signature of genes with altered expression identified by microarray set A was related to iron
uptake and metabolism. Since antibodies specific for E. coli LPS or surface proteins of
A. baumanii were found to be bacteriostatic due to interference with iron uptake (Fitzger-
ald and Rogers, 1980; Goel and Kapil, 2001), this was a very promising finding. However,
qPCR on iron relevant genes validated the microarray results and further supported that
these did not show a difference in the expression level when IVIG samples were compared
to PBS samples. Moreover, qPCR results of dSaIVIG related to PBS treated samples rep-
resented the almost exact reciprocal values of IVIG related to dSaIVIG samples, suggesting
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that the expression of iron related genes was altered due to dSaIVIG treatment, hence not
representing the mechanism underlying bacteriostasis. As iron is essential for basic bac-
terial physiologic processes such as electron transport or nucleotide synthesis (Maresso
and Schneewind, 2006), bacteria evolved several strategies to overcome the iron limitation
in the host environment. Next to the sequestration of heme or transferrin bound iron by
surface proteins (Mazmanian et al., 2003; Reniere et al., 2007), under iron restricted con-
ditions bacteria secrete high affinity iron chelators (siderophores), subsequently enabling
uptake of complexed iron by specialised ABC-transporters (Lindsay and Riley, 1994; Dale
et al., 2004a; Park et al., 2005; Speziali et al., 2006; Miethke and Marahiel, 2007). Since
dSaIVIG is derived from overnight co-incubation with viable S. aureus at 4 ° C it is most
likely that siderophores are secreted as response to the lack of iron in IVIG, thereby supply-
ing S. aureus with pre-existing siderophores and consecutively iron during incubation with
dSaIVIG. Thus, the differential expression of genes related to iron uptake is rather due to
a higher concentration of iron in dSaIVIG treated samples and hence not the mechanism
underlying bacteriostasis.
Another prominent functional group of differentially expressed genes was related to amino-
acid transport and metabolism in both sets of arrays, but apart from the putative carbamoyl-
phosphate synthetase (pyrAA) distinct candidates were identified depending on the em-
ployed control.
Since a reliable signature of genes with altered expression is essential for the analysis
of the mechanism underlying the bacteriostatic effect mediated by S. aureus specific IgGs,
further characterisation based on these results was infeasible. Especially as construction
of allelic replacement mutants of S. aureus is not trivial and highly laborious the number of
investigated genes should be strongly limited.
If IgGs (e. g. purified from IVIG) specific for a single antigen of S. aureus also inhibit
staphylococcal growth, gene expression profiling could be repeated using these instead of
complete IVIG. Hence avoiding the combined action of various IgGs with diverse specifici-
ties, potentially affecting S. aureus. Nevertheless, the problem of many poorly annotated
and characterised genes will persist. Alternatively, since transposon insertion libraries rep-
resent S. aureus mutants deficient for any of the non-essential genes, IVIG could be used
to screen such libraries of S. aureus for mutants, whose growth is no longer inhibited by
specific IgGs present in IVIG. This could enable the direct identification of genes important
for IgG mediated bacteriostasis and might thereby enable the analysis of the underlying
mechanism. Potential drawback of this attempt is the identification of genes not directly
related to bacteriostasis, but for example metabolic pathways, falsely supporting growth in
the presence of otherwise bacteriostatic specific IgGs.
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5.2 Identification and characterisation of potential vaccine candidates
against Staphylococcus aureus
The steadily growing interest in a protective vaccination strategy against S. aureus is re-
flected by numerous studies on active and passive immunisation using a variety of S. aureus
surface components.
Due to their prominent role in immune evasion the capsular polysaccharides (CP) of
S. aureus were in focus of vaccine research. Of the 11 different serotypes of CPs in
S. aureus two, namely Cp5 and CP8, are the predominant serotypes (Thakker et al., 1998),
covering 75 % of all isolates (Arbeit et al., 1984). Although purified CPs are only poorly
immunogenic (Fattom et al., 1990, 1993), conjugation to a non-toxic form of Exotoxin A
from P. aeruginosa as carrier protein vastly enhanced immunogenicity. Furthermore, active
immunisation using a bivalent CP5-CP8 conjugate vaccine (StaphVaxTM; Nabi Biophar-
maceuticals) led to an increased survival rate in mice (Fattom et al., 2004), but failed to
pass the Phase III clinical trial in end stage renal disease patients. A second Phase III
trial in haemodialysis patients also failed, thereby attenuating the development of StaphVax
(Garcia-Lara and Foster, 2009). This failure could be partially due to the fact, that the cap-
sule of S. aureus is no key virulence factor as in other pathogenic bacteria like N. meningi-
tidis and S. pneumoniae, where immunisation with CPs confers more than 90 % protection
(Projan et al., 2006). Besides this, the capsule is produced in the post-exponential phase of
staphylococcal growth, when, since CP expression is under control of the quorum sensing
system agr (Luong et al., 2002), already a high density of bacteria is reached at the site of
infection. This likely hampers sufficient protection in various groups of chronically sick and
immunocompromised patients like end stage renal disease patients (Raskova et al., 1987).
To date several staphylococcal adhesins of the MSCRAMM family have been analysed for
their protective potential in immunisation studies. Despite the positive results achieved, no
monovalent vaccination strategy proved efficacy in clinical trials, in both settings of passive
or active immunisation (Garcia-Lara and Foster, 2009). Hence, it is becoming more and
more obvious that a single target strategy could not confer full protection. This is especially
true, because the function of staphylococcal virulence factors is highly redundant and their
expression is tightly regulated and temporary during the different stages of growth (Bronner
et al., 2004; Boisset et al., 2007).
A first attempt testing a multivalent vaccine was conducted by Stranger-Jones et al.
(2006). In this study the protective capacity of four different members of the MSCRAMM
family containing the LPXTG sorting signal was tested in a murine in vivo sepsis model upon
monovalent immunisation in comparison to a combined vaccine. In contrast to monovalent
immunisation with IsdA, IsdB, SdrD and SdrE the combined vaccine conferred significant
protection from lethal challenge using six different clinical isolates of S. aureus. These
results demonstrate that a highly protective vaccine is feasible, but the challenging task
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remains the identification of eligible candidate proteins (Projan et al., 2006). The major pre-
requisite for a target protein is the expression and accessibility by antibodies under in vivo
conditions. Additionally, the protein should preferably be essential to circumvent the devel-
opment of escape mutants. But in terms of multicomponent vaccines this risk is, due to the
presence of multiple antigens, already markedly decreased. As gene expression is tightly
regulated during the growth of S. aureus, it would be beneficial to combine either constantly
expressed proteins or components expressed at different growth phases, to cover the en-
tire course of growth stages during disease. For example the members of the MSCRAMM
protein family are maximally expressed during early exponential growth and are repressed
in response to agr activation (Cheung et al., 2004; Yarwood and Schlievert, 2003) at the
transition of late exponential to stationary phase, while at the same time toxin and capsule
production is activated.
However, most vaccine studies conducted so far concentrate on MSCRAMM proteins
(Stranger-Jones et al., 2006; Zhou et al., 2006; Arrecubieta et al., 2008). These are co-
valently attached to the staphylococcal peptidoglycan upon recognition of the C-terminally
located conserved LPXTG motif by sortase A (Navarre and Schneewind, 1999) or sortase
B, in case of the iron responsive surface determinants like IsdA and IsdB (Mazmanian et al.,
2002). Due to the conserved LPXTG motif these proteins are readily identified by genome
screenings (Roche et al., 2003; Stranger-Jones et al., 2006). Despite the positive results
achieved by reverse vaccinology for other pathogens like group B streptococcus (Maione
et al., 2005) or serogroup B meningococcus (Giuliani et al., 2006; Pizza et al., 2000), the
major drawback of this bioinformatics-based screening for potential vaccine candidates is
the dependency on conserved sequence motifs. Thus, missing proteins lacking such mo-
tifs or harbouring to date uncharacterised conserved signals, like the group of anchorless
cell wall (ACW) proteins described by Chhatwal (2002). ACW proteins are amongst others
involved in adhesion to host cell structures in several gram-positive bacteria like S. pneu-
monia, S. pyogenes and group A streptococci. Since they lack common signal sequences,
to date it is not known by which mechanism these proteins are secreted (Chhatwal, 2002).
Furthermore, these proteins lack the LPXTG motif or cholin-binding-repeats mediating at-
tachment to the bacterial cell wall. In case of α-enolase from S. pneumonia it was shown
that upon secretion the protein re-associates to the bacterial cell wall (Bergmann et al.,
2001), where it mediates adhesion by binding to laminin and leads to plasminogen activa-
tion. Due to its role in glycolysis enolase also exhibits a pivotal metabolic function, reflected
by the fact that the construction of an enolase deficient isogenic mutant of S. pneumo-
niae was infeasible (Bergmann et al., 2001). In group A streptococci, next to enolase also
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), another glycolytic enzyme, was lo-
calised on the surface, where it mediates adhesion to several mammalian proteins and also
acts as ADP-ribosylating enzyme (Pancholi and Fischetti, 1993, 1998). The multifunctional
roles of the so far characterised ACW proteins renders them promising vaccine candidates.
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Since ACW proteins are not traceable by bioinformatic genome screenings, we applied a
proteomic approach on an ACW-protein preparation from S. aureus for the identification of
potential vaccine candidates. On the basis of serological proteome analysis (SERPA) first
used by Vytvytska et al. (2002), we developed a new procedure of subtractive proteome
analysis, coined SUPRA. To overcome the limitation in source of specific antibodies ac-
companying the use of individual patient sera, an IVIG preparation was employed for the
detection of immunogenic ACW proteins. The IVIG preparations used, contained S. aureus
specific IgGs mediating phagocytosis and killing by human neutrophils (Glowalla et al.,
2009). Potential vaccine candidates were identified by immunodetection of ACW-proteins
using IVIG and IVIG depleted of S. aureus specific IgGs (dSaIVIG). Proteins detected by
IVIG but not, or to a far lesser extent, by dSaIVIG were considered as potential vaccine can-
didates, based on the assumption that those are recognised by naturally occuring S. aureus
specific IgGs, hence representing in vivo expressed immunogenic proteins. In total 39 im-
munogenic proteins matching these criteria were identified. Except for four of these candi-
dates all proteins are present in the 15 currently available completely sequenced genomes
of S. aureus, hence underscoring their broad distribution among S. aureus isolates.
In total, six of these candidates have been characterised regarding their protective po-
tential upon active immunisation in a murine model of sepsis. Whereas immunisation with
enolase (Eno) and oxoacyl-reductase (Oxo) led to a reduction in bacterial load in organs
after intravenous challenge with S. aureus, only immunisation with the hypothetical protein
hp2160 conferred significant protection against lethal challenge with S. aureus ATCC 29213
and USA 300 (Glowalla et al., 2009). Three other candidates, designated BT1, BT2 and
BT3 were in the focus of the current study.
So far next to the pivotal role in the cytoplasm no function on the surface of S. aureus has
been described for BT1, but flow cytometric analysis confirmed its surface localisation.
For BT2 and BT3 important functions in the cytoplasm and on the surface were proven.
For subsequent in vitro and in vivo experiments each of the three candidates (BT1, BT2
and BT3) was cloned and expressed as C-terminal His-Tag fusion protein. To ensure cor-
rect protein folding, the respective fusion proteins were purified under native conditions.
Using IgGs specific for each antigen, enriched from IVIG by affintiy chromatography, the
surface localisation of BT1, BT2 and BT3 of S. aureus strain ATCC 29213 was confirmed
by flow cytometry. Subsequently these antibody fractions were employed as opsonin in in
vitro opsonophagocytosis experiments, revealing that IgGs specific for BT1, BT2 and BT3
promote phagocytosis by human neutrophils. Intriguingly, IgGs specific for BT3 triggered
phagocytosis to a comparable extent as the same amount of IVIG. Since all IgG fractions
triggered phagocytosis also opsonophagocytic killing was assessed using freshly isolated
human neutrophils. Whereas IgGs specific for BT1 mediated elimination of bacteria compa-
rable to IVIG, anti-BT2 IgGs triggered killing of S. aureus to a slightly lower extent. Though
a killing effect could be observed for anti-BT3 IgGs at early time points, this effect did not
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reach statistical significance.
Since the previously obtained results concerning eno, oxo and hp2160 demonstrated that
these in vitro assays are a prerequisite, but are not sufficient to reliably predict the protec-
tive potential in vivo (Glowalla et al., 2009), BalbC mice were immunised with purified BT1,
BT2 and BT3 in complete or incomplete Freund‘s adjuvant for initial and the two booster
immunisations, respectively. Mice immunised with BSA served as controls. The specific
titre for BT1 and BT3 was comparable , whereas immunsiation with BT2 achieved only a
6 to 12 times lower serum titre upon second booster immunisation, indicating a lower im-
munogenicity compared to BT1 and BT3. Accordingly, survival upon lethal challenge with
S. aureus ATCC 29213 was significantly improved only in mice immunised with BT1 and
BT3. Thus representing promising vaccine candidates. In case of BT2 no difference to
BSA immunised mice was observed, hence deferred at first from further analysis. Since
Stranger-Jones et al. (2006) obtained no significant improvement of survival upon single
immunisation with IsdA, IsdB, SdrD and SdrE this exclusion of candidates not conferring
significant protection upon monovalent immunisation could be to stringent, as a combina-
tion of these four antigens conferred full protection. Especially, as IsdA immunised mice
died even earlier than control immunised mice and, as demonstrated by Kim et al. (2010),
passive immunisation using polyclonal rabbit antibodies against IsdA and IsdB prolong sur-
vival upon lethal challenge. Nevertheless, due to its redundant function, BT2 is a weaker
vaccine candidate compared to BT1, BT3 and hp2160.
As proven by the failure or only minor advantages achieved by several monovalent vac-
cination strategies, a multicomponent vaccine seems to be the only reasonable strategy
to prevent and treat S. aureus infections. Therefore, we aimed to identify potential com-
ponents for such a polyvalent vaccine. So far three of the six to date tested candidates
identified by SUPRA confer protection in a murine model of sepsis. Two, namely eno and
oxo achieved at least a reduction of the bacterial load in organs and their failure in con-
ferring protection against lethal challenge could be due to their pronounced homology to
respective murine proteins. To test the potential synergistic effect of BT1 and BT3 upon
combined vaccination, immunisation and subsequent lethal challenge of BalbC mice was
performed in comparison to single immunisations. Unfortunately, no synergistic effect could
be observed under the applied conditions. Whereas BT1 alone still conferred statistically
significant protection, no statistically significant improvement in survival of BT3 immunised
mice could be observed. Though, in contrast to the BSA control group, 30 % more BT3
immunised mice survived the lethal challenge with S. aureus ATCC 29213. The mix was
comparable to monovalent immunisation using BT3. However, only half the amount of each
antigen was used for combined vaccination, to avoid exceeding the total amount of antigen
used for single immunisation. Since the optimal conditions for polyvalent vaccinations are
not sufficiently studied yet, the optimisation of the amount of antigen used in a combined
vaccine might improve the results obtained with the bivalent vaccination using BT1 and
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BT3.
Remarkably SUPRA led to the identification of 39 immunogenic proteins within the ACW-
proteins of S. aureus. The results obtained to date confirmed the efficacy of SUPRA in the
identification of potential vaccine candidates. The gradual characterisation of the remaining
candidates will further increase the number of protective candidates for a multicomponent
vaccine. Combined with other components like IsdA and IsdB as well as the bivalent CP5-
CP8 conjugate a highly protective vaccine against S. aureus could be feasible. Additionally,
the generation of monoclonal antibodies for the most promising candidates like thus far BT1
and BT3 is a definite future objective, to analyse for the protective potential upon passive
immunisation.
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Due to the rapid emergence of S. aureus strains resistant to multiple antibiotics and the
therewith increased mortality rates, the development of alternative strategies to prevent
and treat S. aureus infections is of great clinical and economical importance. Based on the
results concerning both monovalent active and passive immunisation, it is getting obvious
that only multivalent vaccine strategies might confer full protection from S. aureus related
infections. Furthermore, due to their short term applicability and potential composition of
immunoglobulins of different isotypes and functionalities, strategies based on passive im-
munisation are particularly advantageous.
Using an intravenous immunoglobulin preparation (IVIG) as source of naturally occurring
S. aureus specific IgGs, a significant inhibition of staphylococcal growth was observed in
vitro. Thus, confirming the bacteriostatic effect on S. aureus as observed using human
serum in the 1970s. Since this inhibitory effect was not observed upon treatment with
IVIG depleted of S. aureus - specific IgGs (dSaIVIG), bacteriostasis is triggered solely by
S. aureus specific IgGs. In order to analyse the underlying mechanism, gene expression
profiling was conducted, using a S. aureus-seven genome PCR-product microarray. Com-
parison of IVIG to dSaIVIG treated samples led to the identification of 236 differentially
expressed genes over the course of bacteriostasis. In contrast, IVIG compared to PBS
treated samples as additional control resulted in 78 genes with altered expression. Only 13
genes were identified by both sets of microarrays, indicating a strong difference between the
two applied controls. Moreover, the most prominent signature representing genes related
to iron uptake and metabolism was only identified by comparison of IVIG to dSaIVIG sam-
ples. qPCR on iron related genes not only verified the microarray results, but also indicated
that the iron signature was derived from dSaIVIG, thus not representing the mechanism
underlying bacteriostasis. Due to the lack of a reliable signature the mechanism underlying
bacteriostasis could not be characterised.
Additionally, we aimed to enlarge the repertoire of potential candidates for a polyvalent
vaccine. For this purpose a novel subtractive proteomic approach (SUPRA) on anchorless
cell wall (ACW) proteins of S. aureus was developed. This method is based on immunode-
tection of in vivo expressed, immunogenic proteins separated by 2D gelelectrophoresis with
either complete IVIG or dSaIVIG. Proteins immunoreactive with IVIG but not, or to a lesser
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extent using dSaIVIG were identified by MALDI-TOF analysis. SUPRA led to the identifica-
tion of 37 new potential vaccine candidates among ACW proteins. Three of these, BT1, BT2
and BT3 were characterised in this study. The surface localisation of these antigens was
confirmed by flow cytometry using specific antibodies enriched from IVIG. Purified IgGs for
each antigen mediated opsonophagocytosis and subsequent opsonophagocytic killing by
human neutrophils. However, when used for monovalent immunisation of BalbC mice only
BT1 and BT3 conferred significant protection against lethal S. aureus challenge in a murine
model of sepsis. Despite the protective potential upon monovalent immunisation a bivalent
vaccination using BT1 and BT3 did not exhibit a synergistic protective effect, most likely due
to the reduced amount of antigen used for immunisation.
Among the six so far investigated vaccine candidates identified by SUPRA, three con-
ferred protection against lethal challenge with S. aureus (hp2160, BT1 and BT3) and two
led to a reduction of bacterial load in organs (eno and oxo). Therefore, SUPRA represents
a valuable tool for the identification of promising vaccine candidates for subsequent use in
a multicomponent vaccine against S. aureus.
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Bedingt durch die rasante Entstehung multiresistenter S. aureus (MRSA) Stämmen und
der damit einhergehenden gestiegenen Mortalität, ist die Entwicklung alternativer Strate-
gien zur Prävention und Behandlung von S. aureus Infektionen von enormer klinischer
und ökonomischer Bedeutung. Basierend auf den Ergebnissen bisheriger monovalenter
aktiver oder passiver Immunisierungen wird deutlich, dass eine vollständige Protektion vor
S. aureus Infektionen nur durch eine Kombination von verschiedenen Antigenen erzielt wer-
den kann. Außerdem sind, bedingt durch die kurzfristige Anwendbarkeit und die potentielle
Kombination von Immunglobulinen verschiedener Isotypen und Funktionalitäten, Strategi-
en, die auf passiver Immunisierung beruhen, besonders vorteilhaft.
Unter Verwendung einer intravenösen Immunoglobulin Präparation (IVIG) als Quelle na-
türlich vorkommender, S. aureus spezifischer IgGs, konnte eine signifikante Inhibition des
Wachstums von S. aureus beobachtet werden. Somit wurde der in den 1970er Jahren be-
obachtete bakteriostatische Effekt von humanem Serum auf S. aureus bestätigt. Da die-
ser inhibtitorische Effekt nicht beobachtet wurde, wenn S. aureus mit IVIG nach Depleti-
on von spezifischen IgGs (dSaIVIG) kultiviert wurde, vermitteln ausschließlich S. aureus
spezifische IgGs diese Bakteriostase. Um den zugrundeliegenden Mechanismus aufzuklä-
ren, wurde das Gen-Expressionsprofil mittels eines S. aureus spezifischen PCR-Produkt
Mikroarrays ermittelt. Der Vergleich zwischen mit IVIG und dSaIVIG behandelten Proben
führte zur Identifikation von 236 differentiell exprimierten Genen im Verlauf des bakteriosta-
tischen Effektes. Im Gegensatz dazu ergab der Vergleich von IVIG zu mit PBS kultivierten
Staphylokokken als zusätzliche Kontrolle nur 78 Gene mit veränderter Expression. Nur 13
Gene wurden durch beide Mikroarray Analysen identifiziert. Darüber hinaus wurde die auf-
fälligste Signatur von insgesamt 36 Genen, die in in Verbindung mit dem Transport und
Metabolismus von Eisen stehen, nur durch den Vergleich von IVIG mit dSaIVIG identifi-
ziert. Mittels qPCR dieser Gene wurden nicht nur die Mikroarray Daten verifiziert, sondern
zudem gezeigt, dass die Eisen Signatur durch dSaIVIG eingebracht wurde und daher nicht
den Mechanismus drastellen, der der Bakteriostase zugrundeliegt. Da die weitere Analyse
nicht zur Identifikation einer zuverlässigen Signatur geführt hat, konnte der zu Bakteriosta-
sis führende Mechanismus nicht aufgeklärt werden.
Außerdem wollten wir das Repertoire geeigneter Antigene für die Verwendung in einer
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polyvalenten Vakzine gegen S. aureus erweitern. Zu diesem Zweck wurde eine neue sub-
traktive Proteom Analyse (SUPRA) von Zellwand-assoziierten Proteinen von S. aureus ent-
wickelt. Diese Methode basiert auf der Immunodetektion von mittels 2D Gelelektrophorese
aufgetrennten, in vivo exprimierten immunogenen Proteinen mit IVIG oder dSaIVIG. Prote-
ine die mit IVIG, aber nicht oder deutlich geringer mit dSaIVIG detektiert wurden, wurden
mittels MALDI-TOF Analyse identifiziert. SUPRA führte zur Identifikation von 37 neuen po-
tentiellen Vakzinekandidaten in der Gruppe der Zellwand-assoziierten Proteine. Drei dieser
Kandidaten, BT1, BT2 und BT3 wurden in dieser Arbeit charakterisiert. Mittels aus IVIG auf-
gereinigten spezifischen IgGs konnte die Oberflächenlokalisation der drei Proteine mittels
Durchflusszytometrie bestätigt werden. Außerdem vermittelten diese Antikörper Opsono-
phagozytose und anschliessende Elimination durch humane Neutrophile. Nach monova-
lenter Immunisierung von BalbC Mäusen führten jedoch lediglich BT1 und BT3 zu einer
Protektion vor letaler intravenöser Infektion mit S. aureus. Eine bivalente Immunisierung
mit BT1 und BT3 führte allerdings im Vergleich zur Einzelimmunisierung nicht zu einem
synergistischen protektiven Effekt, sehr wahrscheinlich bedingt durch die reduzierte Anti-
genmenge während der Immunisierung.
Von den bisher insgesamt sechs getesteten, durch SUPRA identifizierten Vakzine Kan-
didaten, vermittelten drei Protektion vor letaler Infektion mit S. aureus (hp2160, BT1 und
BT3) und zwei führten zu einer reduzierten Bakterienlast in Organen (eno und oxo). Daher
bietet SUPRA eine wertvolle Methode zur Identifikation vielversprechender Kandidaten für
die Verwendung in einer polyvalenten Immunisierung.
67
8 Bibliography
ANTELMANN, H., H. YAMAMOTO, J. SEKIGUCHI, and M. HECKER, 2002. Stabilization of cell
wall proteins in Bacillus subtilis: a proteomic approach. Proteomics, 2(5) 591–602
ARBEIT, R. D., W. W. KARAKAWA, W. F. VANN, and J. B. ROBBINS, 1984. Predominance
of two newly described capsular polysaccharide types among clinical isolates of Staphy-
lococcus aureus. Diagnostic Microbiology and Infectious Disease, 2(2) 85–91
ARRECUBIETA, C., I. MATSUNAGA, T. ASAI, Y. NAKA, M. C. DENG, and F. D. LOWY, 2008.
Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylo-
coccus aureus infection of an aortic patch in mice. J Infect Dis, 198(4) 571–5
ARVIDSON, S. and K. TEGMARK, 2001. Regulation of virulence determinants in Staphylo-
coccus aureus. Int J Med Microbiol, 291(2) 159–70
BECK, W. D., B. BERGER-BACHI, and F. H. KAYSER, 1986. Additional DNA in methicillin-
resistant Staphylococcus aureus and molecular cloning of mec-specific DNA. J Bacteriol,
165(2) 373–8
BENJAMIN, D. K., R. SCHELONKA, R. WHITE, H. P. HOLLEY, E. BIFANO, J. CUMMINGS,
K. ADCOCK, D. KAUFMAN, B. PUPPALA, P. RIEDEL, B. HALL, J. WHITE, and C. M. COT-
TON, 2006. A blinded, randomized, multicenter study of an intravenous Staphylococcus
aureus immune globulin. J Perinatol, 26(5) 290–5
BENJAMINI, Y. and Y. HOCHBERG, 1995. Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series
B (Methodological), 57(1) 289–300
BERGER-BACHI, B., A. STRASSLE, and F. H. KAYSER, 1986. Characterization of an iso-
genic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur
J Clin Microbiol, 5(6) 697–701
BERGMANN, S., M. ROHDE, G. S. CHHATWAL, and S. HAMMERSCHMIDT, 2001. alpha-
Enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on
the bacterial cell surface. Mol Microbiol, 40(6) 1273–87
68
8 Bibliography
BERNARDO, K., N. PAKULAT, S. FLEER, A. SCHNAITH, O. UTERMÖHLEN, O. KRUT,
S. MÜLLER, and M. KRÖNKE, 2004. Subinhibitory concentrations of linezolid reduce
Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother, 48(2)
546–55
BOISSET, S., T. GEISSMANN, E. HUNTZINGER, P. FECHTER, N. BENDRIDI, M. POSSEDKO,
C. CHEVALIER, A. C. HELFER, Y. BENITO, A. JACQUIER, C. GASPIN, F. VANDENESCH,
and P. ROMBY, 2007. Staphylococcus aureus RNAIII coordinately represses the synthe-
sis of virulence factors and the transcription regulator Rot by an antisense mechanism.
Genes & Development, 21(11) 1353–1366
BRONNER, S., H. MONTEIL, and G. PREVOST, 2004. Regulation of virulence determinants
in Staphylococcus aureus: complexity and applications. FEMS Microbiol Rev, 28(2) 183–
200
CARNEIRO, C. R., E. POSTOL, R. NOMIZO, L. F. REIS, and R. R. BRENTANI, 2004. Identi-
fication of enolase as a laminin-binding protein on the surface of Staphylococcus aureus.
Microbes Infect, 6(6) 604–8
CASADEVALL, A. and L. A. PIROFSKI, 2003. The damage-response framework of microbial
pathogenesis. Nat Rev Microbiol, 1(1) 17–24
CASADEVALL, A. and M. D. SCHARFF, 1994. Serum therapy revisited: animal models of
infection and development of passive antibody therapy. Antimicrob Agents Chemother,
38(8) 1695–702
CHEUNG, A. L., A. S. BAYER, G. ZHANG, H. GRESHAM, and Y.-Q. XIONG, 2004. Regula-
tion of virulence determinants in vitro and in vivo in <i>Staphylococcus aureus</i>. FEMS
Immunology & Medical Microbiology, 40(1) 1–9
CHHATWAL, G. S., 2002. Anchorless adhesins and invasins of Gram-positive bacteria: a
new class of virulence factors. Trends Microbiol, 10(5) 205–8
CLARKE, S. R., K. J. BRUMMELL, M. J. HORSBURGH, P. W. MCDOWELL, S. A. MOHAMAD,
M. R. STAPLETON, J. ACEVEDO, R. C. READ, N. P. DAY, S. J. PEACOCK, J. J. MOND,
J. F. KOKAI-KUN, and S. J. FOSTER, 2006. Identification of in vivo-expressed antigens of
Staphylococcus aureus and their use in vaccinations for protection against nasal carriage.
J Infect Dis, 193(8) 1098–108
CONNOLLY, S. E. and J. L. BENACH, 2001. Cutting Edge: The Spirochetemia of Murine
Relapsing Fever Is Cleared by Complement-Independent Bactericidal Antibodies. J Im-
munol, 167(6) 3029–3032
69
8 Bibliography
CONNOLLY, S. E., D. G. THANASSI, and J. L. BENACH, 2004. Generation of a Complement-
Independent Bactericidal IgM against a Relapsing Fever Borrelia. J Immunol, 172(2)
1191–1197
CORRIERE, M. D. and C. F. DECKER, 2008. MRSA: An Evolving Pathogen. Disease-a-
Month, 54(12) 751–755
DALE, S. E., A. DOHERTY-KIRBY, G. LAJOIE, and D. E. HEINRICHS, 2004a. Role of
siderophore biosynthesis in virulence of Staphylococcus aureus: identification and char-
acterization of genes involved in production of a siderophore. Infect Immun, 72(1) 29–37
DALE, S. E., M. T. SEBULSKY, and D. E. HEINRICHS, 2004b. Involvement of SirABC in
iron-siderophore import in Staphylococcus aureus. J Bacteriol, 186(24) 8356–62
DAROUICHE, R. O., G. C. LANDON, J. M. PATTI, L. L. NGUYEN, R. C. FERNAU, D. MCDE-
VITT, C. GREENE, T. FOSTER, and M. KLIMA, 1997. Role of Staphylococcus aureus
surface adhesins in orthopaedic device infections: are results model-dependent? J Med
Microbiol, 46(1) 75–9
DAVIS, S. L., M. J. RYBAK, M. AMJAD, G. W. KAATZ, and P. S. MCKINNON, 2006.
Characteristics of patients with healthcare-associated infection due to SCCmec type IV
methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol, 27(10) 1025–
31
DEJONGE, M., D. BURCHFIELD, B. BLOOM, M. DUENAS, W. WALKER, M. POLAK, E. JUNG,
D. MILLARD, R. SCHELONKA, F. EYAL, A. MORRIS, B. KAPIK, D. ROBERSON, K. KESLER,
J. PATTI, and S. HETHERINGTON, 2007. Clinical trial of safety and efficacy of INH-A21 for
the prevention of nosocomial staphylococcal bloodstream infection in premature infants.
J Pediatr, 151(3) 260–5, 265 e1
EHRENKRANZ, N. J., D. F. ELLIOTT, and R. ZARCO, 1971. Serum Bacteriostasis of Staphy-
lococcus aureus. Infect Immun, 3(5) 664–670
VON EIFF, C., K. BECKER, K. MACHKA, H. STAMMER, and G. PETERS, 2001. Nasal Car-
riage as a Source of Staphylococcus aureus Bacteremia. N Engl J Med, 344(1) 11–16
FATTOM, A., S. FULLER, M. PROPST, S. WINSTON, L. MUENZ, D. HE, R. NASO, and
G. HORWITH, 2004. Safety and immunogenicity of a booster dose of Staphylococ-
cus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in
hemodialysis patients. Vaccine, 23(5) 656–63
FATTOM, A., R. SCHNEERSON, S. C. SZU, W. F. VANN, J. SHILOACH, W. W. KARAKAWA,
and J. B. ROBBINS, 1990. Synthesis and immunologic properties in mice of vaccines
70
8 Bibliography
composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conju-
gated to Pseudomonas aeruginosa exotoxin A. Infect Immun, 58(7) 2367–74
FATTOM, A., R. SCHNEERSON, D. C. WATSON, W. W. KARAKAWA, D. FITZGERALD, I. PAS-
TAN, X. LI, J. SHILOACH, D. A. BRYLA, and J. B. ROBBINS, 1993. Laboratory and clinical
evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type
8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein
A. Infect. Immun., 61(3) 1023–1032
FITZGERALD, J. R., D. E. STURDEVANT, S. M. MACKIE, S. R. GILL, and J. M. MUSSER,
2001. Evolutionary genomics of Staphylococcus aureus: Insights into the origin of
methicillin-resistant strains and the toxic shock syndrome epidemic. Proceedings of the
National Academy of Sciences of the United States of America, 98(15) 8821–8826
FITZGERALD, S. P. and H. J. ROGERS, 1980. Bacteriostatic effect of serum: role of antibody
to lipopolysaccharide. Infect. Immun., 27(2) 302–308
FOSTER, T. J., 2005. Immune evasion by staphylococci. Nat Rev Microbiol, 3(12) 948–58
FOSTER, T. J. and M. HOOK, 1998. Surface protein adhesins of Staphylococcus aureus.
Trends Microbiol, 6(12) 484–8
GARCIA-LARA, J. and S. J. FOSTER, 2009. Anti-Staphylococcus aureus immunotherapy:
current status and prospects. Curr Opin Pharmacol, 9(5) 552–7
GIESE, M. J., S. A. ADAMU, H. PITCHEKIAN-HALABI, R. M. RAVINDRANATH, and B. J.
MONDINO, 1996. The effect of Staphylococcus aureus phage lysate vaccine on a rab-
bit model of staphylococcal blepharitis, phlyctenulosis, and catarrhal infiltrates. Am J
Ophthalmol, 122(2) 245–54
GIULIANI, M. M., J. ADU-BOBIE, M. COMANDUCCI, B. ARICO, S. SAVINO, L. SAN-
TINI, B. BRUNELLI, S. BAMBINI, A. BIOLCHI, B. CAPECCHI, E. CARTOCCI, L. CIUC-
CHI, F. DI MARCELLO, F. FERLICCA, B. GALLI, E. LUZZI, V. MASIGNANI, D. SERRUTO,
D. VEGGI, M. CONTORNI, M. MORANDI, A. BARTALESI, V. CINOTTI, D. MANNUCCI,
F. TITTA, E. OVIDI, J. A. WELSCH, D. GRANOFF, R. RAPPUOLI, and M. PIZZA, 2006.
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A, 103(29)
10834–9
GLOWALLA, E., B. TOSETTI, M. KRÖNKE, and O. KRUT, 2009. Proteomics-based iden-
tification of anchorless cell wall proteins as vaccine candidates against Staphylococcus
aureus. Infect Immun, 77(7) 2719–29
71
8 Bibliography
GOEL, V. and A. KAPIL, 2001. Monoclonal antibodies against the iron regulated outer
membrane Proteins of Acinetobacter baumannii are bactericidal. BMC Microbiology, 1(1)
16
GONZALEZ, B. E., A. M. RUEDA, R. SHELBURNE, S. A., D. M. MUSHER, R. J. HAMILL,
and K. G. HULTEN, 2006. Community-associated strains of methicillin-resistant Staphy-
lococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp
Epidemiol, 27(10) 1051–6
GREENBERG, D. P., J. I. WARD, and A. S. BAYER, 1987. Influence of Staphylococcus
aureus antibody on experimental endocarditis in rabbits. Infect Immun, 55(12) 3030–4
HIRAMATSU, K., H. HANAKI, T. INO, K. YABUTA, T. OGURI, and F. C. TENOVER, 1997.
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin sus-
ceptibility. J Antimicrob Chemother, 40(1) 135–6
HORSBURGH, M. J., M. O. CLEMENTS, H. CROSSLEY, E. INGHAM, and S. J. FOSTER,
2001a. PerR controls oxidative stress resistance and iron storage proteins and is required
for virulence in Staphylococcus aureus. Infect Immun, 69(6) 3744–54
HORSBURGH, M. J., E. INGHAM, and S. J. FOSTER, 2001b. In Staphylococcus aureus,
fur is an interactive regulator with PerR, contributes to virulence, and Is necessary for
oxidative stress resistance through positive regulation of catalase and iron homeostasis.
J Bacteriol, 183(2) 468–75
HU, D. L., K. OMOE, S. SASAKI, H. SASHINAMI, H. SAKURABA, Y. YOKOMIZO, K. SHINA-
GAWA, and A. NAKANE, 2003. Vaccination with nontoxic mutant toxic shock syndrome
toxin 1 protects against Staphylococcus aureus infection. J Infect Dis, 188(5) 743–52
JOSEFSSON, E., O. HARTFORD, L. O’BRIEN, J. M. PATTI, and T. FOSTER, 2001. Protection
against experimental Staphylococcus aureus arthritis by vaccination with clumping factor
A, a novel virulence determinant. J Infect Dis, 184(12) 1572–80
KAMPEN, A. H., T. TOLLERSRUD, and A. LUND, 2005. Staphylococcus aureus Capsular
Polysaccharide Types 5 and 8 Reduce Killing by Bovine Neutrophils In Vitro. Infect.
Immun., 73(3) 1578–1583
KIM, H. K., A. DEDENT, A. G. CHENG, M. MCADOW, F. BAGNOLI, D. M. MISSIAKAS, and
O. SCHNEEWIND, 2010. IsdA and IsdB antibodies protect mice against Staphylococcus
aureus abscess formation and lethal challenge. Vaccine, In Press, Uncorrected Proof
KING, M. D., B. J. HUMPHREY, Y. F. WANG, E. V. KOURBATOVA, S. M. RAY, and H. M.
BLUMBERG, 2006. Emergence of community-acquired methicillin-resistant Staphylococ-
72
8 Bibliography
cus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections.
Ann Intern Med, 144(5) 309–17
KLEVENS, R. M., M. A. MORRISON, J. NADLE, S. PETIT, K. GERSHMAN, S. RAY, L. H.
HARRISON, R. LYNFIELD, G. DUMYATI, J. M. TOWNES, A. S. CRAIG, E. R. ZELL, G. E.
FOSHEIM, L. K. MCDOUGAL, R. B. CAREY, and S. K. FRIDKIN, 2007. Invasive methicillin-
resistant Staphylococcus aureus infections in the United States. Jama, 298(15) 1763–71
KLUYTMANS, J., A. VAN BELKUM, and H. VERBRUGH, 1997. Nasal carriage of Staphylococ-
cus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol.
Rev., 10(3) 505–520
KRONVALL, G. and K. JONSSON, 1999. Receptins: a novel term for an expanding spec-
trum of natural and engineered microbial proteins with binding properties for mammalian
proteins. J Mol Recognit, 12(1) 38–44
LADHANI, S., S. M. POSTON, C. L. JOANNOU, and R. W. EVANS, 1999. Staphylococcal
scalded skin syndrome: exfoliative toxin A (ETA) induces serine protease activity when
combined with A431 cells. Acta Paediatr, 88(7) 776–9
LAUPLAND, K. B., D. L. CHURCH, M. MUCENSKI, L. R. SUTHERLAND, and H. D. DAVIES,
2003. Population-based study of the epidemiology of and the risk factors for invasive
Staphylococcus aureus infections. J Infect Dis, 187(9) 1452–9
LINDSAY, J. A. and T. V. RILEY, 1994. Staphylococcal iron requirements, siderophore
production, and iron-regulated protein expression. Infect Immun, 62(6) 2309–14
LLEWELYN, M. and J. COHEN, 2002. Superantigens: microbial agents that corrupt immu-
nity. The Lancet Infectious Diseases, 2(3) 156–162
LOWY, F. D., 1998. Staphylococcus aureus infections. N Engl J Med, 339(8) 520–32
LUONG, T., S. SAU, M. GOMEZ, J. C. LEE, and C. Y. LEE, 2002. Regulation of Staphy-
lococcus aureus Capsular Polysaccharide Expression by agr and sarA. Infect. Immun.,
70(2) 444–450
MAIONE, D., I. MARGARIT, C. D. RINAUDO, V. MASIGNANI, M. MORA, M. SCARSELLI,
H. TETTELIN, C. BRETTONI, E. T. IACOBINI, R. ROSINI, N. D’AGOSTINO, L. MIORIN,
S. BUCCATO, M. MARIANI, G. GALLI, R. NOGAROTTO, V. NARDI DEI, F. VEGNI,
C. FRASER, G. MANCUSO, G. TETI, L. C. MADOFF, L. C. PAOLETTI, R. RAPPUOLI,
D. L. KASPER, J. L. TELFORD, and G. GRANDI, 2005. Identification of a universal Group
B streptococcus vaccine by multiple genome screen. Science, 309(5731) 148–50
73
8 Bibliography
MAIRA-LITRAN, T., A. KROPEC, D. GOLDMANN, and G. B. PIER, 2004. Biologic properties
and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysac-
charide. Vaccine, 22(7) 872–9
MARESSO, A. W. and O. SCHNEEWIND, 2006. Iron acquisition and transport in Staphylo-
coccus aureus. Biometals, 19(2) 193–203
MAZMANIAN, S. K., E. P. SKAAR, A. H. GASPAR, M. HUMAYUN, P. GORNICKI, J. JELENSKA,
A. JOACHMIAK, D. M. MISSIAKAS, and O. SCHNEEWIND, 2003. Passage of heme-iron
across the envelope of Staphylococcus aureus. Science, 299(5608) 906–9
MAZMANIAN, S. K., H. TON-THAT, K. SU, and O. SCHNEEWIND, 2002. An iron-regulated
sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis.
Proc Natl Acad Sci U S A, 99(4) 2293–8
MIETHKE, M. and M. A. MARAHIEL, 2007. Siderophore-Based Iron Acquisition and
Pathogen Control. Microbiol. Mol. Biol. Rev., 71(3) 413–451
MIETHKE, T., C. WAHL, K. HEEG, B. ECHTENACHER, P. KRAMMER, and H. WAGNER, 1992.
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal entero-
toxin B: critical role of tumor necrosis factor. J. Exp. Med., 175(1) 91–98
NAVARRE, W. W. and O. SCHNEEWIND, 1999. Surface proteins of gram-positive bacteria
and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev, 63(1)
174–229
NILSSON, I. M., J. M. PATTI, T. BREMELL, M. HOOK, and A. TARKOWSKI, 1998. Vaccination
with a recombinant fragment of collagen adhesin provides protection against Staphylo-
coccus aureus-mediated septic death. J Clin Invest, 101(12) 2640–9
PANCHOLI, V. and V. A. FISCHETTI, 1993. Glyceraldehyde-3-phosphate dehydrogenase on
the surface of group A streptococci is also an ADP-ribosylating enzyme. Proceedings of
the National Academy of Sciences of the United States of America, 90(17) 8154–8158
PANCHOLI, V. and V. A. FISCHETTI, 1998. alpha-Enolase, a Novel Strong Plasmin(ogen)
Binding Protein on the Surface of Pathogenic Streptococci. Journal of Biological Chem-
istry, 273(23) 14503–14515
PAPPIN, D. J., P. HOJRUP, and A. J. BLEASBY, 1993. Rapid identification of proteins by
peptide-mass fingerprinting. Curr Biol, 3(6) 327–32
PARK, R. Y., H. Y. SUN, M. H. CHOI, Y. H. BAI, and S. H. SHIN, 2005. Staphylococcus
aureus siderophore-mediated iron-acquisition system plays a dominant and essential role
in the utilization of transferrin-bound iron. J Microbiol, 43(2) 183–90
74
8 Bibliography
PATEL, A. H., P. NOWLAN, E. D. WEAVERS, and T. FOSTER, 1987. Virulence of protein
A-deficient and alpha-toxin-deficient mutants of Staphylococcus aureus isolated by allele
replacement. Infect Immun, 55(12) 3103–10
PATTI, J. M., B. L. ALLEN, M. J. MCGAVIN, and M. HOOK, 1994. MSCRAMM-mediated
adherence of microorganisms to host tissues. Annu Rev Microbiol, 48 585–617
PEACOCK, S. J., T. J. FOSTER, B. J. CAMERON, and A. R. BERENDT, 1999. Bacterial
fibronectin-binding proteins and endothelial cell surface fibronectin mediate adherence
of Staphylococcus aureus to resting human endothelial cells. Microbiology, 145 ( Pt 12)
3477–86
PERL, T. M., J. J. CULLEN, R. P. WENZEL, M. B. ZIMMERMAN, M. A. PFALLER, D. SHEP-
PARD, J. TWOMBLEY, P. P. FRENCH, L. A. HERWALDT, T. MUPIROCIN, and THE RISK OF
STAPHYLOCOCCUS AUREUS STUDY TEAM, 2002. Intranasal Mupirocin to Prevent Post-
operative Staphylococcus aureus Infections. N Engl J Med, 346(24) 1871–1877
PIZZA, M., V. SCARLATO, V. MASIGNANI, M. M. GIULIANI, ARIC, OGRAVE, B. , M. CO-
MANDUCCI, G. T. JENNINGS, L. BALDI, E. BARTOLINI, B. CAPECCHI, C. L. GALEOTTI,
E. LUZZI, R. MANETTI, E. MARCHETTI, M. MORA, S. NUTI, G. RATTI, L. SANTINI,
S. SAVINO, M. SCARSELLI, E. STORNI, P. ZUO, M. BROEKER, E. HUNDT, B. KNAPP,
E. BLAIR, T. MASON, H. TETTELIN, EACUTE, D. W. HOOD, A. C. JEFFRIES, N. J.
SAUNDERS, D. M. GRANOFF, J. C. VENTER, E. R. MOXON, G. GRANDI, and R. RAP-
PUOLI, 2000. Identification of Vaccine Candidates Against Serogroup B Meningococcus
by Whole-Genome Sequencing. Science, 287(5459) 1816–1820
POUTREL, B., A. BOUTONNIER, L. SUTRA, and J. M. FOURNIER, 1988. Prevalence of
capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow,
goat, and ewe milk. J Clin Microbiol, 26(1) 38–40
PROJAN, S. J., M. NESIN, and P. M. DUNMAN, 2006. Staphylococcal vaccines and im-
munotherapy: to dream the impossible dream? Curr Opin Pharmacol, 6(5) 473–9
RASKOVA, J., I. GHOBRIAL, D. K. CZERWINSKI, S. M. SHEA, R. P. EISINGER, and
J. RASKA, KAREL, 1987. B-Cell Activation and Immunoregulation in End-Stage Renal
Disease Patients Receiving Hemodialysis. Arch Intern Med, 147(1) 89–93
RENIERE, M. L., V. J. TORRES, and E. P. SKAAR, 2007. Intracellular metalloporphyrin
metabolism in Staphylococcus aureus. Biometals, 20(3-4) 333–45
ROCHE, F. M., M. MEEHAN, and T. J. FOSTER, 2003. The Staphylococcus aureus surface
protein SasG and its homologues promote bacterial adherence to human desquamated
nasal epithelial cells. Microbiology, 149(10) 2759–2767
75
8 Bibliography
RUPP, M. E., J. HOLLEY, H. P., J. LUTZ, P. V. DICPINIGAITIS, C. W. WOODS, D. P. LEVINE,
N. VENEY, and J. FOWLER, V. G., 2007. Phase II, randomized, multicenter, double-blind,
placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccha-
ride immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob
Agents Chemother, 51(12) 4249–54
SCHAFFER, A. C., R. M. SOLINGA, J. COCCHIARO, M. PORTOLES, K. B. KISER, A. RISLEY,
S. M. RANDALL, V. VALTULINA, P. SPEZIALE, E. WALSH, T. FOSTER, and J. C. LEE,
2006. Immunization with Staphylococcus aureus clumping factor B, a major determinant
in nasal carriage, reduces nasal colonization in a murine model. Infect Immun, 74(4)
2145–53
SCHNEEWIND, O., A. FOWLER, and K. F. FAULL, 1995. Structure of the cell wall anchor of
surface proteins in Staphylococcus aureus. Science, 268(5207) 103–6
SOMPOLINSKY, D., Z. SAMRA, W. W. KARAKAWA, W. F. VANN, R. SCHNEERSON, and
Z. MALIK, 1985. Encapsulation and capsular types in isolates of Staphylococcus aureus
from different sources and relationship to phage types. J Clin Microbiol, 22(5) 828–34
SPEZIALI, C. D., S. E. DALE, J. A. HENDERSON, E. D. VINES, and D. E. HEINRICHS,
2006. Requirement of Staphylococcus aureus ATP-binding cassette-ATPase FhuC for
iron-restricted growth and evidence that it functions with more than one iron transporter.
J Bacteriol, 188(6) 2048–55
STAPLETON, M. R., M. J. HORSBURGH, E. J. HAYHURST, L. WRIGHT, I. M. JONSSON,
A. TARKOWSKI, J. F. KOKAI-KUN, J. J. MOND, and S. J. FOSTER, 2007. Characteriza-
tion of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus. J
Bacteriol, 189(20) 7316–25
STRANGER-JONES, Y. K., T. BAE, and O. SCHNEEWIND, 2006. Vaccine assembly from
surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A, 103(45) 16942–7
TENOVER, F. C., L. K. MCDOUGAL, R. V. GOERING, G. KILLGORE, S. J. PROJAN, J. B.
PATEL, and P. M. DUNMAN, 2006. Characterization of a strain of community-associated
methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J
Clin Microbiol, 44(1) 108–18
THAKKER, M., J.-S. PARK, V. CAREY, and J. C. LEE, 1998. Staphylococcus aureus
Serotype 5Â Capsular Polysaccharide Is Antiphagocytic and Enhances Bacterial Viru-
lence in a Murine Bacteremia Model. Infect. Immun., 66(11) 5183–5189
TOMITA, T. and Y. KAMIO, 1997. Molecular biology of the pore-forming cytolysins from
Staphylococcus aureus, alpha- and gamma-hemolysins and leukocidin. Biosci Biotechnol
Biochem, 61(4) 565–72
76
8 Bibliography
VERNACHIO, J. H., A. S. BAYER, B. AMES, D. BRYANT, B. D. PRATER, P. J. SYRIBEYS,
E. L. GOROVITS, and J. M. PATTI, 2006. Human immunoglobulin G recognizing
fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and
Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother, 50(2) 511–
8
VYTVYTSKA, O., E. NAGY, M. BLUGGEL, H. E. MEYER, R. KURZBAUER, L. A. HUBER,
and C. S. KLADE, 2002. Identification of vaccine candidate antigens of Staphylococcus
aureus by serological proteome analysis. Proteomics, 2(5) 580–90
WEIGEL, L. M., D. B. CLEWELL, S. R. GILL, N. C. CLARK, L. K. MCDOUGAL, S. E. FLAN-
NAGAN, J. F. KOLONAY, J. SHETTY, G. E. KILLGORE, and F. C. TENOVER, 2003. Genetic
analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science,
302(5650) 1569–71
WEISMAN, L. E., 2007. Antibody for the prevention of neonatal noscocomial staphylococcal
infection: a review of the literature. Arch Pediatr, 14 Suppl 1 S31–4
WEISMAN, L. E., H. M. THACKRAY, J. A. GARCIA-PRATS, M. NESIN, J. H. SCHNEIDER,
J. FRETZ, J. F. KOKAI-KUN, J. J. MOND, W. G. KRAMER, and G. W. FISCHER, 2009. A
Phase 1/2 Double Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacoki-
netic Study in Very Low Birth Weight Neonates of Pagibaximab (BSYX-A110), an Anti-
Staphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream
Infections. Antimicrob. Agents Chemother., pp. AAC.01565–08
WERTHEIM, H. F. L., J. VERVEER, H. A. M. BOELENS, A. VAN BELKUM, H. A. VERBRUGH,
and M. C. VOS, 2005. Effect of Mupirocin Treatment on Nasal, Pharyngeal, and Perineal
Carriage of Staphylococcus aureus in Healthy Adults. Antimicrob. Agents Chemother.,
49(4) 1465–1467
WITNEY, A. A., G. L. MARSDEN, M. T. HOLDEN, R. A. STABLER, S. E. HUSAIN, J. K.
VASS, P. D. BUTCHER, J. HINDS, and J. A. LINDSAY, 2005. Design, validation, and appli-
cation of a seven-strain Staphylococcus aureus PCR product microarray for comparative
genomics. Appl Environ Microbiol, 71(11) 7504–14
YARWOOD, J. M. and P. M. SCHLIEVERT, 2003. Quorum sensing in Staphylococcus infec-
tions. The Journal of Clinical Investigation, 112(11) 1620–1625
ZHOU, H., Z. Y. XIONG, H. P. LI, Y. L. ZHENG, and Y. Q. JIANG, 2006. An immunogenicity
study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus
infections in a mice model. Vaccine, 24(22) 4830–7
77
9 Supplement
Table 9.1: Differentially expressed genes in IVIG versus dSaIVIG and IVIG versus PBS
Common a) Predicted function GI protein
t0 t30 t60
FC 1 b) FC 2 c) FC 1 b) FC 2 c) FC 1 b) FC 2 c)
bglA 6-phospho-beta-glucosidase 49482503 7.0 3.9
fabG 3-oxoacyl-[acyl-carrier protein] reductase 49483394 1.9 1.7
menH put. 2-heptaprenyl-1,4-naphthoquinone 49483658 -1.8 -1.5
methyltransferase
pyrAA put. carbamoyl-phosphate synthase 49483365 1.7 -1.8 -1.9
SAR0331 put. membrane protein 49482566 -2.1 -1.7 -2.1
SAR0874 conserved hypothetical protein 49483072 2.0 1.7
SAR1599 put. geranyltranstransferase 49483771 -1.5 -2.3 -2.5
SAR1684 conserved hypothetical protein 49483850 1.7 2.5 2.1
SAR1849 proline dehydrogenase 49484011 -2.6 2.6
SAR1854 hypothetical protein 49484016 -1.9 -1.9
SAR1879 put. lipoprotein 49484040 2.3 3.2
SAR2408 PTS system, arbutin-like IIBC component 49484538 -2.3 -6.5 -2.8
set15 superantigen-like protein 15923423 -9.3 -2.5
a) Prefix SAR, MRSA252 gene ID
b) fold change of gene expression in IVIG related to dSaIVIG treated sample
c) fold change of gene expression in IVIG related to PBS treated sample
Table 9.2:
List of the 236 differentially expressed genes in IVIG compared to dSaIVIG treated samples
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
agrB put. autoinducer processing protein 49484262 2.4 0.025
arcA arginine deiminase 49484832 -2.3 0.046 -2.1 0.012
arcB put. ornithine carbamoyltransferase 49484831 -1.7 0.012 -1.8 0.023
argG put. argininosuccinate synthase 49483121 -3.1 0.017 -2.1 0.017
argH put. argininosuccinate lyase 49483120 -2.9 0.015 -1.8 0.012
asp23 alkaline shock protein 23 49484402 3.0 0.028
bglA 6-phospho-beta-glucosidase 49482503 7.0 0.033
citC isocitrate dehydrogenase 49483936 3.1 0.031
citZ citrate synthase II 49483937 3.6 0.036
clfB fibrinogen and keratin-10 binding surface anchored
protein
49484827 -1.8 0.017
a) Prefix SA, N315 gene ID; SACOL, COL gene ID; SAOUHSC, NCTC8325 gene ID; SAR, MRSA252 gene ID; SAV, Mu50 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
Continued on next page. . .
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List of the 236 differentially expressed genes in IVIG compared to dSaIVIG treated samples (con-
tinued)
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
coa staphylocoagulase precursor [conserved region] 49482463 -1.8 0.036 -8.9 0.014
crtN squalene synthase 49484762 2.4 0.026
cycA put. D-serine/D-alanine/glycine transporter 49483938 1.6 0.017
dltA D-alanine-D-alanyl carrier protein ligase 49483092 1.9 0.012
dnaA chromosomal replication initiator protein DnaA 49482254 -1.8 0.020
dnaN DNA polymerase III, beta chain 49482255 -1.7 0.017 -1.9 0.040
fabG 3-oxoacyl-[acyl-carrier protein] reductase 49483394 1.9 0.017
fda fructose-bisphosphate aldolase class I 49484802 1.7 0.031
fhuA ferrichrome transport ATP-binding protein 49482875 2.3 0.026 1.9 0.016
fhuB ferrichrome transport permease 49482876 2.1 0.026
fhuD ferrichrome transport permease 49482877 2.0 0.036 1.8 0.017
fnb fibronectin-binding protein precursor -2.3 0.026
fnbA fibronectin-binding protein precursor 49484704 -2.8 0.014
fnbB fibronectin-binding protein precursor 15928081 -2.2 0.018
fur iron uptake regulatory protein 49483748 -1.5 0.019
glcB PTS system, glucose-specific IIABC component 49484739 3.6 0.036
glnA glutamine synthetase 49483472 2.3 0.015
gyrB DNA gyrase subunit B 49482258 -1.8 0.017
hemC porphobilinogen deaminase 49483913 -1.6 0.014
hemD uroporphyrinogen III synthase 49483912 -1.5 0.012 -1.7 0.017
icaD intercellular adhesion protein D 49484862 -1.7 0.019
ilvC ketol-acid reductoisomerase 49484281 -3.1 0.019
isdA iron-regulated heme-iron binding protein 49483292 2.9 0.030 1.6 0.026
isdC put. surface anchored protein 49483293 2.7 0.019 2.7 0.020
isdI heme-degrading monooxygenase 49482408 1.7 0.049 2.3 0.043 2.2 0.038
leuD 3-isopropylmalate dehydratase small subunit 49484285 -1.7 0.026 -1.6 0.025
menH put. 2-heptaprenyl-1,4-naphthoquinone methyl-
transferase
49483658 -1.5 0.035
mtlA PTS system, mannitol-specific IIBC component 49484378 -1.8 0.019
narG nitrate reductase alpha chain 49484613 -4.2 0.017
ndk put. nucleoside diphosphate kinase 49483656 -1.7 0.025
nrdD anaerobic ribonucleoside-triphosphate reductase 49484813 -1.6 0.021
nuc thermonuclease precursor 49483047 -2.3 0.017
opuD2 glycine betaine transporter 2 49484405 2.6 0.039
phoB alkaline phosphatase III precursor (pseudogene) 49487405 -1.6 0.026 -1.6 0.035
proP put. proline/betaine transporter 49482802 1.8 0.028 1.8 0.014
purA put. adenylosuccinate synthetase 49482270 -1.7 0.026
purC put. phosphoribosylaminoimidazole-succinocar-
boxamide synthase
49483230 -1.7 0.015
purD put. phosphoribosylamine-glycine ligase 49483238 -2.2 0.015
purE put. phosphoribosylaminoimidazole carboxylase
catalytic subunit
49483228 -1.5 0.016 -1.7 0.039
purH put. bifunctional purine biosynthesis protein 49483237 -3.0 0.021 -1.7 0.019
purL put. phosphoribosylformylglycinamidine synthase II 49483233 -3.5 0.022 -1.9 0.024 -1.8 0.018
purM put. phosphoribosylformylglycinamidine cyclo-
ligase
49483235 -2.7 0.017 -1.6 0.026
purQ put. phosphoribosylformylglycinamidine synthase I 49483232 -2.0 0.016 -1.5 0.038
a) Prefix SA, N315 gene ID; SACOL, COL gene ID; SAOUHSC, NCTC8325 gene ID; SAR, MRSA252 gene ID; SAV, Mu50 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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List of the 236 differentially expressed genes in IVIG compared to dSaIVIG treated samples (con-
tinued)
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
pyrAA put. carbamoyl-phosphate synthase, pyrimidine-
specific, small chain
49483365 1.7 0.015 -1.8 0.050
pyrAB put. carbamoyl-phosphate synthase, pyrimidine-
specific, large chain
49483366 1.7 0.029 -1.8 0.047
pyrC put. dihydroorotase 49483364 2.1 0.016 -1.8 0.034
pyrF put. orotidine 5’-phosphate decarboxylase 49483367 1.6 0.049
pyrP put. uracil permease 49483362 2.2 0.016
recF DNA replication and repair protein RecF 49482257 -2.3 0.029
ribA riboflavin biosynthesis protein 49484013 4.3 0.024 20.8 0.006 8.5 0.013
ribD bifunctional riboflavin biosynthesis protein 49484015 4.7 0.017 16.7 0.006 7.7 0.012
ribE riboflavin synthase alpha chain 49484014 3.9 0.049 13.6 0.019 8.0 0.013
ribH 6,7-dimethyl-8-ribityllumazine synthase 49484012 3.3 0.036 12.9 0.006 6.4 0.013
rnaIII rnaIII regulatory transcript containing the delta-
hemolysin structural gene
49484261 2.0 0.033
rpsU 30S ribosomal protein S21 49483823 -1.6 0.031 -1.8 0.016
rsbV anti-sigma B factor antagonist 49484292 1.9 0.017
SA0191 put. RND family efflux transporter 15925901 -1.5 0.017
SA0222v staphylocoagulase precursor [conserved region] -3.0 0.042
SA0743 similar to staphylocoagulase precursor 15926465 -3.3 0.018
SA1001 formyl peptide receptor-like 1 inhibitory protein 15926739 -1.7 0.017
SA1633 beta-lactamase 15927389 -1.6 0.032
SACOL1381 exonuclease SbcD 57650350 1.7 0.043
SACOL1510 polyprenyl synthetase 57650425 -1.6 0.017
SACOL1511 ubiquinone/menaquinone biosynthesis methyl-
transferase
57650426 -1.6 0.019
SACOL1542 MutT/nudix family protein 57650455 -1.7 0.019
SACOL1719 glutamyl-tRNA reductase 57650544 2.0 0.012
SACOL1975 nicotinate phosphoribosyltransferase 57650665 2.3 0.019 2.2 0.013
SAOUHSC_02559 urease beta subunit 88196204 -3.5 0.034
SAOUHSC_02727 hypothetical protein 88196367 -2.8 0.033
SAOUHSC_03644 1.8 0.012
SAR0012 put. hydrolase 49482265 -1.9 0.029
SAR0110 put. Na+/Pi-cotransporter protein 49482350 -2.0 0.020
SAR0148 hypothetical protein 49482389 -1.8 0.028
SAR0172 conserved hypothetical protein 49482413 2.6 0.024
SAR0174 put. lipoprotein 49482415 1.9 0.046
SAR0176 conserved hypothetical protein 49482417 2.5 0.025
SAR0212 put. membrane protein 49482453 -1.8 0.015 -3.8 0.017
SAR0221 hypothetical protein 49482462 -1.9 0.017
SAR0230 put. extracellular solute-binding lipoprotein 49482471 -1.6 0.015
SAR0231 conserved hypothetical protein 49482472 -1.9 0.015 -1.8 0.017
SAR0233 flavohemoprotein 49482474 -2.1 0.012
SAR0238 put. PTS multi-domain regulator (pseudogene) -1.6 0.032
SAR0240 put. PTS transport system, IIA component 49482479 -2.2 0.019
SAR0262 GntR family regulatory protein 49482501 2.6 0.018
SAR0263 put. PTS transport system protein 49482502 6.9 0.027
SAR0271 put. transport protein 49482511 2.6 0.036 1.9 0.018
SAR0299 hypothetical protein 49482535 -1.8 0.023
a) Prefix SA, N315 gene ID; SACOL, COL gene ID; SAOUHSC, NCTC8325 gene ID; SAR, MRSA252 gene ID; SAV, Mu50 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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List of the 236 differentially expressed genes in IVIG compared to dSaIVIG treated samples (con-
tinued)
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
SAR0301 put. membrane protein 49482536 -1.8 0.023
SAR0320 put. bacterial luciferase family protein 49482555 1.9 0.037
SAR0321 put. glycine cleavage H-protein 49482556 2.3 0.006
SAR0324 put. lipoate-protein ligase A 49482559 1.9 0.034
SAR0331 put. membrane protein 49482566 -1.7 0.038
SAR0332 hypothetical protein 49482567 -2.0 0.033
SAR0390 put. lipoprotein 49482621 2.5 0.019
SAR0405 hypothetical protein 49482638 2.0 0.027
SAR0411 hypothetical protein 49482643 -1.6 0.026
SAR0438 put. lipoprotein 49482665 -1.5 0.035
SAR0458 sodium:neurotransmitter symporter family protein 49482683 -1.9 0.030
SAR0522 put. pyridoxine biosynthesis protein 49482748 2.4 0.044 2.8 0.042
SAR0523 SNO glutamine amidotransferase family protein 49482749 2.6 0.031 3.3 0.025
SAR0624 put. esterase 49482845 2.2 0.030
SAR0722 put. transposase 49482926 -1.8 0.039
SAR0735 put. exported protein 49482938 1.5 0.025
SAR0760 put. membrane protein 49482963 -1.9 0.017
SAR0763 put. radical activating enzyme 49482966 3.0 0.012
SAR0764 put. 6-pyruvoyl tetrahydropterin synthase 49482967 2.7 0.012
SAR0765 conserved hypothetical protein 49482968 2.4 0.015
SAR0805 conserved hypothetical protein 49483008 -1.6 0.039 -1.8 0.026
SAR0854 hypothetical protein 49483054 2.0 0.013
SAR0855 hypothetical protein 49483055 1.8 0.018
SAR0861 nitroreductase family protein 49483062 2.1 0.034 1.9 0.025
SAR0874 conserved hypothetical protein 49483072 2.0 0.032
SAR0893 put. membrane protein 49483091 1.7 0.015
SAR0905 put. transporter protein 49483103 -1.9 0.020
SAR1010 put. membrane protein 49483202 -1.8 0.035
SAR1041 conserved hypothetical protein 49483231 -1.7 0.017
SAR1049 put. cobalt transport protein 49483239 2.9 0.019
SAR1050 ABC transporter ATP-binding protein 49483240 3.2 0.017
SAR1051 put. membrane protein 49483241 2.8 0.017
SAR1052 hypothetical protein 49483242 -1.7 0.016 -1.6 0.019
SAR1059 put. cytochrome ubiquinol oxidase 49483249 -1.7 0.017 -1.6 0.041
SAR1060 put. membrane protein 49483250 -1.6 0.021 -1.6 0.025
SAR1088 put. pyruvate carboxylase 49483277 -1.5 0.017
SAR1127 put. exported protein 49483317 -4.0 0.019
SAR1210 put. chromosome partition protein 49483397 -1.6 0.026
SAR1253 conserved hypothetical protein 49483440 -1.5 0.035
SAR1263 hypothetical protein 49483450 2.2 0.017
SAR1281 conserved hypothetical protein 49483469 -2.0 0.035
SAR1285 hypothetical protein 49483473 2.0 0.015
SAR1344 catalase 49483526 -2.8 0.019 -2.0 0.017
SAR1347 put. GMP reductase 49483529 -2.1 0.017
SAR1398 put. phosphate transport system protein 49483576 -1.8 0.026
SAR1399 ABC transporter ATP-binding protein 49483577 -1.7 0.021
SAR1400 ABC transporter permease protein 49483578 -1.9 0.033
SAR1419 put. branched-chain amino acid transporter protein 49483597 -1.8 0.012
a) Prefix SA, N315 gene ID; SACOL, COL gene ID; SAOUHSC, NCTC8325 gene ID; SAR, MRSA252 gene ID; SAV, Mu50 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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List of the 236 differentially expressed genes in IVIG compared to dSaIVIG treated samples (con-
tinued)
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
SAR1445 put. membrane protein 49483623 1.5 0.017
SAR1446 conserved hypothetical protein 49483624 -1.7 0.017
SAR1454 put. membrane protein (pseudogene) -1.9 0.012
SAR1471 put. membrane protein 49483649 -1.7 0.015
SAR1472 put. membrane protein 49483650 -2.3 0.016
SAR1473 conserved hypothetical protein 49483651 -1.8 0.013
SAR1493 put. membrane protein 49483671 2.1 0.019 2.0 0.017
SAR1499 hypothetical phage protein 49483676 -4.0 0.035
SAR1599 put. geranyltranstransferase 49483771 -1.5 0.041
SAR1620 put. membrane protein 49483792 -1.8 0.045 -1.9 0.025
SAR1664 conserved hypothetical protein 49483834 -1.8 0.026
SAR1683 put. membrane protein 49483849 1.7 0.019 3.1 0.026
SAR1684 conserved hypothetical protein 49483850 1.7 0.019 2.5 0.034
SAR1687 conserved hypothetical protein 49483853 1.6 0.019 2.2 0.045
SAR1704 hypothetical protein 49483869 2.0 0.035
SAR1705 conserved hypothetical protein 49483870 1.9 0.035
SAR1848 conserved hypothetical protein 49484010 1.8 0.019 1.6 0.012
SAR1849 proline dehydrogenase 49484011 2.6 0.021
SAR1854 hypothetical protein 49484016 -1.9 0.019
SAR1879 put. lipoprotein 49484040 2.3 0.028
SAR1880 put. membrane protein 49484041 2.4 0.038
SAR1919 enterotoxin 49484069 -1.8 0.026
SAR1921 enterotoxin 49484071 -1.7 0.026
SAR1973 put. membrane protein 49484124 2.0 0.022
SAR1984 ferritin 49484134 -2.5 0.035 -4.6 0.019 -3.9 0.017
SAR1985 put. exonuclease 49484135 -2.2 0.030
SAR2016 put. exported protein 49484165 1.8 0.012
SAR2227 put. non-heme iron-containing ferritin 49484363 -2.8 0.017
SAR2228 conserved hypothetical protein 49484364 -1.8 0.016
SAR2232 conserved hypothetical protein 49484368 2.7 0.017
SAR2265 put. membrane protein 49484394 -2.7 0.028 -1.9 0.019
SAR2266 FecCD transport family protein 49484395 3.3 0.030 2.3 0.023
SAR2268 put. transport system binding lipoprotein 49484397 5.7 0.019 3.7 0.019
SAR2269 hypothetical protein 49484398 2.3 0.028
SAR2270 hypothetical protein 49484400 2.4 0.019
SAR2271 put. membrane protein 49484400 2.6 0.017
SAR2274 put. membrane protein 49484403 3.1 0.026
SAR2275 put. membrane protein 49484404 1.6 0.012 3.4 0.028
SAR2296 conserved hypothetical protein 49484426 -2.7 0.012
SAR2297 put. acetolactate synthase 49484427 -2.8 0.013
SAR2338 xanthine/uracil permeases family protein 49484469 -1.8 0.013
SAR2364 FdhD/NarQ family protein 49484495 -1.5 0.034
SAR2368 put. ferrichrome-binding lipoprotein precursor 49484499 2.4 0.039
SAR2392 conserved hypothetical protein 49484524 -2.1 0.026
SAR2393 put. bifunctional protein 49484525 -2.1 0.022
SAR2403 put. membrane protein 49484535 -2.9 0.012 -3.2 0.034 -2.2 0.017
SAR2408 PTS system, arbutin-like IIBC component 49484538 -2.3 0.021 -6.5 0.036
SAR2413 put. short chain dehydrogenase 49484543 2.0 0.017
a) Prefix SA, N315 gene ID; SACOL, COL gene ID; SAOUHSC, NCTC8325 gene ID; SAR, MRSA252 gene ID; SAV, Mu50 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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List of the 236 differentially expressed genes in IVIG compared to dSaIVIG treated samples (con-
tinued)
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
SAR2420 arginase family protein 49484548 1.9 0.017
SAR2429 put. 3-methylpurine glycosylase 49484559 -1.7 0.037 -1.6 0.017
SAR2460 put. acetyltransferase (GNAT) family protein 49484589 2.0 0.026
SAR2469 conserved hypothetical protein 49484598 1.8 0.017
SAR2487 tetrapyrrole (corrin/porphyrin) methylase family
protein
49484614 -1.6 0.016
SAR2558 conserved hypothetical protein 49484685 2.0 0.012
SAR2561 conserved hypothetical protein 49484688 2.2 0.017
SAR2621 put. membrane protein 49484742 -4.8 0.018
SAR2641 put. aminotransferase 49484761 1.5 0.017
SAR2645 put. glycosyl transferase 49484763 3.0 0.017
SAR2646 put. phytoene dehydrogenase related protein 49484764 2.6 0.017
SAR2647 put. membrane protein 49484765 2.0 0.023
SAR2739 conserved hypothetical protein 49484853 1.7 0.017
SAR2773 conserved hypothetical protein 49484886 2.5 0.020
SAR2777 put. DNA-binding protein 49484890 1.8 0.012
SAR2791 put. membrane protein 49484901 -1.6 0.017
sarR staphylococcal accessory regulator A homologue 49484510 -1.6 0.033
SAV0206v staphylocoagulase precursor [conserved region] -5.2 0.019
SAV0902 hypothetical protein 15923892 -1.5 0.019
sbi IgG-binding protein 49484634 -3.8 0.017
sbnA pyridoxal-phosphate dependent enzyme 49482359 3.4 0.033
sbnB put. ornithine cyclodeaminase 49482360 4.5 0.017
sbnC put. siderophore biosynthesis protein 49482361 3.9 0.012
sbnD put. transport protein 49482362 3.0 0.012
sbnE put. siderophore biosynthesis protein 49482363 3.0 0.017
sbnF put. siderophore biosynthesis protein 49482364 2.5 0.017
sbnG put. aldolase 49482365 2.8 0.012
sbnH pyridoxal-dependent decarboxylase decarboxylase 49482366 2.1 0.012
sbnI hypothetical protein 49482367 2.3 0.012
set15 superantigen-like protein 15923423 -9.3 0.029
sigB RNA polymerase sigma-B factor 49484290 1.8 0.017
sirA lipoprotein 49482358 7.5 0.019 4.1 0.018
sirB put. siderophore transport system permease 49482357 5.5 0.019 3.3 0.017
sirC put. siderophore transport system permease 49482356 3.3 0.038
spa immunoglobulin G binding protein A precursor 49482354 1.6 0.017
srtB sortase B 49483297 5.1 0.037 3.4 0.012
sstA FecCD transport family protein 49482990 3.4 0.034
sstB FecCD transport family protein 49482991 5.0 0.032 3.7 0.028
sstC ABC transporter ATP-binding protein 49482992 2.3 0.025 7.4 0.019 4.5 0.017
sstD lipoprotein 49482993 8.9 0.019 4.3 0.017
thiM put. hydroxyethylthiazole kinase 49484316 3.5 0.032
ureA urease gamma subunit 49484503 1.6 0.020
yycH put. exported protein 49482273 -1.7 0.029
a) Prefix SA, N315 gene ID; SACOL, COL gene ID; SAOUHSC, NCTC8325 gene ID; SAR, MRSA252 gene ID; SAV, Mu50 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
83
9 Supplement
Table 9.3: List of the 78 differentially expressed genes in IVIG compared to PBS treated samples
Commona) Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
bglA 6-phospho-beta-glucosidase SAR0264 49482503 3.9 0.043
fabG 3-oxoacyl-[acyl-carrier protein] reductase 49483394 1.7 0.045
fdaB fructose 1,6 bisphosphate aldolase 88196553 2.2 0.037
fruA PTS transport system, fructose-specific IIABC
component
49482956 1.8 0.043
fumC fumarate hydratase, class-II SAR1942 49484093 2.1 0.044
glpD aerobic glycerol-3-phosphate dehydrogenase 49483464 3.0 0.037
glpF put. glycerol uptake facilitator protein 49483462 5.3 0.043
glpK glycerol kinase 49483463 5.2 0.037
hisS histidyl-tRNA synthetase 49483876 -1.9 0.043
hup DNA-binding protein HU 49483660 1.6 0.033 1.7 0.029
isaA immunodominant antigen A 49484768 1.8 0.029
kbl put. 2-amino-3-ketobutyrate coenzyme A ligase 49482780 3.2 0.043
lysP lysine-specific permease 49483924 -1.6 0.015
menH put. 2-heptaprenyl-1,4-naphthoquinone methyl-
transferase
49483658 -1.8 0.020
mvaS 3-hydroxy-3-methylglutaryl coenzyme A synthase 49484747 1.9 0.037
oppB put. oligopeptide transport system permease
protein
49483147 -2.1 0.020
oppC put. oligopeptide transport system permease
protein
49483148 -1.8 0.033 -2.1 0.017
purB adenylosuccinate lyase 49484149 1.8 0.029
pyrAA put. carbamoyl-phosphate synthase, pyrimidine-
specific, small chain
49483365 -1.9 0.043
rocD ornithine aminotransferase 49483117 -1.7 0.017
rpsG 30S ribosomal protein S7 49482776 1.8 0.016
SACOL3503 1.7 0.018
SAR0205 put. maltose ABC transporter, ATP-binding protein 49482446 -2.4 0.016
SAR0243 put. zinc-binding dehydrogenase 49482482 -1.8 0.037
SAR0312 put. N-acetylneuraminate lyase 49482547 -2.0 0.016
SAR0331 put. membrane protein 49482566 -2.1 0.018 -2.1 0.043
SAR0367 DNA-binding protein 49482600 2.4 0.037
SAR0490 tetrapyrrole (corrin/porphyrin) methylase family
protein
49482716 -1.7 0.037
SAR0521 GntR family regulatory protein/ regulatory protein 49482747 -1.8 0.033 -1.8 0.015 -1.8 0.037
SAR0642 ABC transporter permease protein 49482860 -1.7 0.043
SAR0643 ABC transporter ATP-binding protein 49482861 -1.6 0.037
SAR0786 ribonucleoside-diphosphate reductase beta chain 49482989 -1.7 0.043
SAR0871 ABC transporter permease protein 49483070 -1.7 0.015
SAR0872 put. lipoprotein /NLPA lipoprotein 49483071 -1.8 0.033
SAR0874 conserved hypothetical protein / CsbD-like super-
family protein
49483072 1.7 0.037
SAR0920 put. NAD-specific glutamate dehydrogenase 49483118 4.0 0.043
SAR0996 conserved hypothetical protein 49483190 -2.9 0.021
SAR1227 conserved hypothetical protein 49483414 1.6 0.033
SAR1338 put. homoserine dehydrogenase 49483520 -4.6 0.031
SAR1345 50S ribosomal protein L33 type 2 49483527 1.6 0.015
SAR1377 ImpB/MucB/SamB family protein 49483558 -1.8 0.029
a) Prefix SACOL, COL gene ID; SAR, MRSA252 gene ID; SAS, MSSA476 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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List of the 78 differentially expressed genes in IVIG compared to PBS treated samples (continued)
Common Predicted function GI protein
t0 t30 t60
FCb) p-valuec) FCb) p-valuec) FCb) p-valuec)
SAR1455 put. exported protein 49483632 -1.7 0.038
SAR1481 hypothetical protein 49483659 -1.8 0.037
SAR1599 put. geranyltranstransferase 49483771 -2.3 0.019 -2.5 0.045
SAR1610 lipoate-protein ligase A protein 49483782 -2.2 0.038
SAR1684 conserved hypothetical protein 49483850 2.1 0.043
SAR1686 put. biotin carboxyl carrier protein of acetyl-CoA
carboxylase
49483852 -1.8 0.020
SAR1693 put. O-methyltransferase 49483859 -1.7 0.037
SAR1702 put. cysteine desulfurase 49483867 -1.6 0.033
SAR1703 put. oxygenase 49483868 -1.7 0.037
SAR1756 hypothetical protein 49483919 -1.9 0.037
SAR1849 proline dehydrogenase 49484011 -2.6 0.021
SAR1854 hypothetical protein 49484016 -1.9 0.045
SAR1879 put. lipoprotein 49484040 3.2 0.037
SAR1881 put. lipoprotein 49484042 2.1 0.043
SAR1883 hypothetical protein 49484044 1.9 0.045
SAR1916 enterotoxin 49484066 -1.7 0.039
SAR2052 hypothetical phage protein 49484199 2.0 0.029
SAR2399 put. transcription regulator 49484531 -1.7 0.037
SAR2408 PTS system, arbutin-like IIBC component 49484538 -2.8 0.017
SAR2409 put. transcription regulator 49484539 -1.8 0.045
SAR2467 conserved hypothetical protein 49484596 3.1 0.043
SAR2589 put. glucarate transporter 49484713 6.4 0.037
SAR2596 conserved hypothetical protein 49484720 3.5 0.045
SAR2651 put. membrane protein 49484769 -2.1 0.016
SAR2664 hypothetical protein 49484782 -1.7 0.037
SAR2682 put. aminotransferase 49484800 -2.5 0.017
SAR2688 hypothetical protein 49484806 -1.9 0.033
SAR2737 conserved hypothetical protein 15925646 -1.6 0.037
SAR2744 put. capsule synthesis protein 49484858 -1.6 0.015 -1.8 0.037
SAS0036 DNA replication and repair protein RecF 49484948 1.8 0.043
sasF put. surface anchored protein 49484843 -1.9 0.029 -1.7 0.037
scrR sucrose operon repressor 49484268 2.1 0.043
sdrE bone sialoprotein-binding protein [conserved
region]
49482792 -1.6 0.015
set15 exotoxin 15 15926111 -2.5 0.047
tcaR MarR family regulatory protein 49484572 -1.8 0.047
thl acetyl-CoA acetyltransferase 49482584 1.6 0.043
uhpT put. sugar phosphate transport protein 49482454 -2.6 0.029
a) Prefix SACOL, COL gene ID; SAR, MRSA252 gene ID; SAS, MSSA476 gene ID
b) fold change of gene expression in IVIG treated samples
c) p-value was determined by t-test including Benjamini-Hochberg correction
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